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The generation of anti-drug antibodies (ADAs) is a major concern in biotherapeutic drug 
development. It is now well acknowledged that therapeutic protein aggregation is intimately 
connected with the host immune response which affects the drug effectiveness. All protein 
aggregates, however, are not equally immunogenic and what kind of biophysical and 
biochemical nature makes an aggregate more immunogenic than others is yet well understood. 
In this research dissertation, I focused on understanding the conformational and biochemical 
nature of amorphous aggregates related to immune responses and the long-term effects of 
those immune responses on drug safety measurements. I divided this dissertation into four 
chapters.    
In chapter 1, I reviewed some of the intrinsic and extrinsic factors connected with the 
immunogenic aspects of a therapeutic protein with particular focus on therapeutic protein 
aggregation and oligomerization. Additionally, I discussed the immunological mechanisms 
that are related to protein aggregates and generating anti-drug antibodies (ADAs). Amorphous 
aggregates, unlike amyloids, possess distinct morphology with diverse biochemical and 
biophysical nature, and are further classified based on their size, reversibility, chemical 
modifications and so on. Several clinical studies showed that therapeutic protein aggregates 
are responsible for unwanted immunogenicity, however, very little is known about the 
aggregate’s nature that is related to clinical immunogenicity. Therefore, I summarized some 
of the in vivo experimental studies that are aimed to connect the biophysical and biochemical 
parameters of the protein aggregates with immunogenicity. Aggregates can potentially 
generate the immune response (B-cells activation) with the help of T-cell, so-called T-cell 
dependent pathways, or without any help of T-cells.   
In chapter 2, I examined the immunogenicity of an anti-EGFR VHH (VHH-7D12), a potential 
anti-cancer drug, and four different aggregates state. Firstly, I produced two heat-induced VHH 
aggregates, incubated at 65 °C for 45 min (VHH-65) and 95 °C for 110 min (VHH-95). 
Additionally, I isolated a low-soluble misfolded VHH species from an E.coli lysate during 
refolding of the VHH protein (VHH-Ins). To mimic the VHH-Ins, I also deliberately generated a 





immunological experiments were carried out at a protein concentration of 0.3 mg/mL in 
phosphate saline buffer (PBS, pH 7.4). Circular dichroism (CD) measurements indicated that 
the secondary structural content of the native VHH-7D12 was typical of a β-sheeted protein. 
The secondary structure of VHH-Ins and VHH-Mis was completely different from native VHH-
7D12. Similarly, tryptophan and ANS (8-Anilinonaphthalene-1-sulfonic acid) fluorescence 
measurements showed a different tertiary structure content of VHH-Ins and VHH-Mis. On the 
other hand, VHH-65 showed only a minor change in their secondary and tertiary structures. 
Surface plasmon resonance (SPR) showed that the native VHH-7D12 binds to EGFR, a target 
ligand of VHH-7D12, in a concentration-dependent manner. VHH-65 showed slight decreasing 
activity. The misfolded VHH formulations (VHH-Ins and VHH-Mis) and VHH-95 completely lost 
their binding activity with EGFR. Further, the size of the VHH aggregates was measured by 
dynamic light scattering (DLS). The Z-ave hydrodynamic radius of native VHH was 3.5 ± 0.19 
nm, as expected for monomeric VHH. VHH-Ins and VHH-Mis in PBS (pH 7.4) formed 
aggregates larger than 1 µm (1846.5 ± 409.4 and 1951 ± 373.3, respectively). VHH-95 formed 
aggregates that are very similar in size to misfolded VHH (1722 ± 179 nm), whereas VHH-65 
produced aggregates smaller than 1 µm (771.3 ± 26.3 nm). Finally, in vivo immunization 
experiments were performed in mice and the generation of anti-drug antibodies (ADAs), 
mainly IgG, was determined by ELISA. The results showed that native VHH-7D12 was 
scarcely immunogenic, as expected for small proteins, while VHH-65 was mildly 
immunogenic. The misfolded aggregates, VHH-Ins and VHH-Mis, showed higher IgG response. 
By contrast, the heat-denatured aggregates, VHH-95, having a Z-ave and aggregation 
propensity similar to that of misfolded VHHs (VHH-Ins and VHH-Mis), was not immunogenic 
at all. These findings indicate the critical role of biophysical and biochemical attributes of the 
amorphous aggregates in the generation of an immune response against a protein rather than 
just their size. 
 
In chapter 3, I reported the immunogenic nature, especially the specificity of the immune 
response induced by VHH-Mis (misfolded VHH-7D12) and their long-term anti-therapeutic 
effects. To do so, I used an analogous anti-EGFR VHH (VHH-9G8), along with VHH-7D12, 





but distinct complementary determining regions (CDRs), the functional part of the VHH 
antibody. The anti-sera raised against the VHH-Mis was further analyzed by ELISA using 
native VHH-7D12 and native VHH-9G8 as coating antigens. This is because we anticipated 
seeing cross-reactions because of their identical framework regions. As a result, we observed 
that 60 % of the mice (8 out of 13) immunized with VHH-Mis the IgG titer against native VHH-
7D12 was much stronger than against native VHH-9G8 (Group-1), indicating that IgG was 
directed against the regions that are specific for VHH-7D12, eg VHH-7D12’s CDRs. The 
remaining 40 % of mice (5 out 13) showed a very similar IgG titer against the native VHH-
7D12 and native VHH-9G8 (Group-2). We rationalized these results by hypothesizing that the 
IgG was mostly generated against the VHH’s frameworks that are common for both VHHs. The 
long-term immunological experiments showed that the pattern of IgG specificity against 
native VHH-7D12 and VHH-9G8 was essentially unchanged over 17 weeks. After 17 weeks 
without injection, both groups of mice (Group-1 and Group-2) were re-immunized with 
native VHH-7D12 and VHH-9G8 (boost injection). As a result, we observed that  Group-1 mice 
increased the IgG titer sharply when re-immunized with native VHH-7D12 but not with native 
VHH-9G8, indicating that the immunological memory was generated against VHH-7D12, 
particularly against the VHH-7D12’s CDRs. On the other hand, the IgG titer of the Group-2 
mice increased by re-immunizing both of the VHHs, indicating that immunological memory 
was generated against the framework regions. Finally, the flow-cytometric analysis showed 
that VHH-Mis immunized mice generated a higher number of effector and central T-cell 
memory. Overall these observations indicate that the amorphous aggregates of misfolded VHH 
can induce serum IgG and immunological memory against the native self and with a nill to 
moderate immune response against natively folded VHH analogs. Our findings indeed suggest 
that by determining the ADAs specificity one might avoid ADAs’ appearance by switching 
the therapeutic antibody to an analogus one that targets the same EGFR and would thus allow 
the same therapeutic strategy. 
In chapter 4, I concluded the overall observations of chapter 2 and chapter 3 and discussed the 
future aspect of this research. The above studies clearly suggested that native monomeric VHH 
proteins barely affect immunogenicity. The aggregated species definitely increase the 
immunogenicity but solely depending on the nature of the aggregates. So far, many of the 





generate ADAs, but counter-examples have led to some controversy. Our observations 
provided sound evidence that the biophysical and biochemical nature of the aggregates plays 
a major role rather than just their size. Moreover, the aggregates made of misfolded VHHS can 
carry the higher risk of immunogenicity with CDRs (active-site of an antibody drug) specific 
ADAs and carry the long term-immunogenicity risk. I believe that this research will have a 



























1.1 Therapeutic protein immunogenicity 
Immunogenicity of therapeutic protein indicates the host immune responses that unwantedly 
generated against drug molecules, resulting in anti-drug antibodies (ADAs) [1]. The ADAs 
response unexpectedly reduces the therapeutic effectiveness of a protein drug, and thereby, 
worsening the existing disease conditions. For instance, the recombinant factor VIII resulted 
in ADAs generation of approximately 30 % of haemophilia A patients, which significantly 
inhibit the hemostatic efficiency of factor VIII [2]. Likewise, ADAs development against 
interferon (IFN)-β, a relapsing-remitting multiple sclerosis (MS) drug, can inhibit IFN-β 
binding to its receptor, reducing drug efficacy and accelerating disease progressions [3]. 
Moreover, even though rarely, ADAs may have strong cross-reactivity with host endogenous 
proteins, as observed for the recombinant EPO and thrombopoietins [4-6]. ADAs may have 
drug function neutralizing capacity when the epitope is located at the active-site of the drug 
molecules, while non-neutralizing ADAs recognize regions other than the active-sites [7]. 
However, in both cases, either neutralizing or non-neutralizing, ADAs negatively affect the 
pharmacokinetics and pharmacodynamics of the drug by accelerating the clearance from the 
body [7]. 
Therapeutic monoclonal antibodies (mAbs), one of the fast-growing classes of 
biopharmaceutical products, often provoke ADAs, either in a form of neutralizing or non-
neutralizing/binding [8]. The first mouse monoclonal antibody, muromonab-CD3, approved 
by the FDA induced ADAs in 50% of the patients [9]. Similarly, another murine antibody, 
edrecolomab, showed undesired immune responses in all (100%) of the patients [10]. Even 
though antibody humanization technology can significantly reduce the fate of 
immunogenicity, still many of the antibody therapeutics show immune response, in a form of 
ADAs. For example, adalimumab, the first fully-humanized monoclonal antibody (mAb) 
showed immunogenicity in 5% of adult patients with rheumatoid arthritis [11].  In the next 






1.2 Factors related to therapeutic protein immunogenicity 
Several intertwined factors are connected with the immune responses against a protein-based 
therapeutic drug, which are broadly classified into three key categories: (1) treatment-related 
factors (2) patient-related factors and (3) product-related factors (Figure 1.1) [12]. Treatment-
related factors, which include duration and frequency of the treatment and eventually the route 
of drugs administration, have an influential effect on immunogenicity. Generally, long-term 
therapy is more likely to induce immunogenicity than short-term therapy. One of the well-
known examples is the formation of ADAs against various IFN-b products that required 
different amounts of time [13]. On the other hand, when considering the route of 
administration, it is evidenced that subcutaneous (SC) injection is more susceptible to increase 
the immunogenicity other than intravenous (IV) or intramuscular (IM) injection [14]. The 
higher immunogenic nature of this route is described by their two-wave antigen presentations 
(Figure 1.2) [15]. Nevertheless, subcutaneous injection is most desirable due to patient 
comfort and compliance. Moreover, this route of administration increases the drugs serum 
half-life. Intramuscular (IM) administration is also likely to elicit an immune response, but to 
a lesser extent, when compared with intravenous (IV) administration [15]. 
Beyond the treatment-related factors, genetic background of the patients, like the inherent 
polymorphism of human proteins, can often influence immunogenicity. A well-established 
clinical example with haemophilia patients showed that the genetic defect of the factor VIII 
gene determines whether an individual will or will not produce ADAs [16, 17]. Another study, 
conducted by Scharrer et al. showed that race can be a risk factor for generating antibodies 
[18].  
Protein sequence, a critical product-related factor, can cause unwanted immune responses. 
Usually, non-humanized proteins are highly immunogenic, as a human immune system 
identifying those molecules as foreign and respond accordingly. As observed for the 
monoclonal antibodies derived from the murine system, which showed higher 
immunogenicity in human. For example, muromonab-CD3, the first mouse monoclonal 
antibody approved by the FDA, showed binding antibodies in 50% of the patients [9]. 
Similarly, a murine antibody, edrecolomab, showed undesired immune response in all of 




influence its immunogenicity. Such a phenomenon has been reported for factor VIII, where 
ADAs generation was related to their pasteurization stage in the manufacturing process. It has 
also been reported that the product impurities and contaminants are associated with antibody 
development, as shown for insulin and growth hormone products [19]. Experimental studies 
with ovalbumin showed that trace amounts of impurities are sufficient enough to break the 
immune tolerance against ovalbumin [20]. However, this problem is now decreasing as the 
purity of products improves.  
Among other product-related factors, protein aggregation is identified as the most critical. One 
of the earlier clinical evidence showed that human growth hormone (hGH) reduced its 
undesired immunogenicity by removing the accidental aggregates from the formulations [21, 
22]. Some of the other examples regarding aggregates initiated immunogenicity are comprised 
of erythropoietin (EPO), factor VIII. Therefore, several drug regulatory agencies have paid 
attention to their guideline to control therapeutic protein aggregation. European Medical 
Agency (EMA) considered visible and sub-visible aggregates as risk factor and stating, “The 
formation of aggregates, sub-visible and visible particulates in the drug product is important 
and should be investigated and closely monitored on the batch release and during stability 
study” (REF).  Food and Drug Administration (FDA) state that “Assessment should be made 
of the range and level of sub-visible particle (2-10 µm) present in the therapeutic protein 
product initially and over the course of the shelf life”. 
 
1.3 Immunogenic response to therapeutic protein aggregates 
From early clinical studies in the 1960s to more recent examples, it has been found that 
aggregated therapeutic proteins can adversely affect the host immune response, resulting in 
ADAs formation [23, 24]. One of the first studies has been reported by Christian [25, 26] in 
early 1960, where aggregates of human gamma globulin (hGG) induced by heat showed 
immunogenicity in human volunteers as well as guinea pigs and rats. In the later stage, Ellis 
and Henney showed strong evidence of aggregate initiated immune response [27]. They 
separated the monomer and aggregated hGG from three commercially available hGG 
formulations and injected intradermally. As a result, hGG in monomeric form did not cause 




showed a strong sensitivity reaction (flares-and-wheals). Similarly, clinical studies with 
human growth hormones (hGH) showed that removing aggregated particles from drug 
formulations significantly reduced the antibody formation against hGH [22]. The neutralizing 
ADAs generation was observed against recombinant human erythropoietin (EPO) when drug 
formulation and administration schemes were changed [5]. Several hypotheses, even though 
controversial, indicated the role of micelles formation. Besides several clinical observations, 
where detection and characterization of aggregates are rarely performed, to date, many 
experimental studies have reported the possible contribution of aggregates in ADAs 
generation. However, it is becoming increasingly clear that all aggregate types do not induce 
equal immune responses in the host. Many intertwined factors are thought to be related to the 
immune response to protein aggregates, including aggregates biophysical and biochemical 
nature such as the structural/folding properties, size, availability and frequency of neo-
epitopes, amount of aggregates and so on are influential and are still under investigation [28, 
29].  
 
1.3.1 Aggregate’s structure/conformation and immunogenicity 
A natively functional protein has a complex three-dimensional structure. Any physical 
instability, such as unfolding or misfolding can result in protein aggregation, which further 
increases immunogenicity. In clinical studies, where the aggregates nature is not accurately 
monitored and characterized, several experimental studies show a relationship between the 
aggregate’s structure/biophysical properties and immunogenicity. Aggregates containing 
native-like structures are proposed to be more immunogenic [30, 31]. A well-known example 
is the immunogenicity of factor VIII, which readily formed both native-like or non-native 
aggregates depending on the way they are generated [32-34]. Immunization experiments using 
transgenic mice showed that native-like aggregates were more immunogenic than native 
monomeric factor VIII and non-native aggregates of factor VIII. In another study, Fathallah 
et al. showed that native-like monoclonal antibody aggregates were more immunogenic than 
denatured aggregates [35]. Recent studies have demonstrated that non-native aggregates may 
induce potent antibody responses, but due to their non-native structure, it is expected that they 




1.3.2 Aggregate’s size and immunogenicity  
Size is one of the important factors used to classify the protein aggregates. Fathallah et al. [35] 
have documented the immunogenicity based on the aggregate size. Small oligomers (<100 
nm) and non-native micron size aggregates were generated using heat stress and protein 
unfolding models. They revealed that a small oligomeric protein was much more 
immunogenic than a non-native micron size aggregate. To explore more on the aggregate size 
based immunogenicity, Kijanka et al. [37] conducted their study using a monoclonal antibody 
in which the antibody was subjected to heat stress to generate different sizes of aggregates. 
The aggregates were fractionated using low-speed centrifugation and size exclusion 
chromatography and further classified into a soluble oligomer, sub-micron size and micron 
size aggregates. Immunization experiments with Balb/c mice revealed that submicron size 
(0.1-1 µm) formulation was more immunogenic than micron size (1-100 µm) and soluble 
oligomer enriched fractions. These findings are partly contradict by Fathallah et al., where 
less than 100 nm size oligomers were reported to be highly immunogenic but both research 
groups documented the non-immunogenic properties of micron size aggregates. Likewise, 
micron size aggregates of single chain variable fragment (ScFv) did not show any increase 
immunogenicity than native monomeric ScFv [38]. In another study, Boll et al. [39] attempted 
to address the immunological effect of chemical modification along with aggregate size. The 
sample formulation contained the same size aggregate (15 µm) but with a different level of 
chemical modification. Immunization experimentation in the mice model showed that extreme 
chemical modification was required to break the immune tolerance of the micron size 
aggregates. Suggesting that biochemical properties of aggregates are important in addition to 
size in breaking immune tolerance. In recent study, using bovine pancreatic trypsin inhibitor 
(BPTI) protein Rahman et al. showed that a few nanometer size protein aggregates can break 
the immune tolerance [40]. Overall, there is no solid consensus regarding the relationship 
between the aggregates size and immunogenicity, suggesting that other aggregates nature 







1.4 Protein aggregation 
Protein aggregation is one of the most common routes of protein instability, making the 
protein product unfit for basic academic research to clinical application. Protein aggregation 
is generally defined as the abnormal intermolecular interaction of protein molecules, having 
its natively folded, partially unfolded, misfolded or even completely denatured state (Figure 
1.3) [41, 42]. Depending on the pathway and the environment, the structurally altered protein 
may initially form a small dimer, trimer and/or tetramer and in thermodynamically favourable 
conditions further progress toward sub-visible to visible sizes [43]. Despite numerous attempts 
to shed light on the pathway of aggregate formation and their associated factors over 60 years, 
still, there is no solid consensus regarding the protein aggregation pathway and its systematic 
control [44]. This is because of the diverse types and nature of the aggregates, which are 
poorly understood due to the difficulties in their specific isolation and detailed experimental 
characterization. 
 
1.4.1 Factors influencing protein aggregation 
Protein aggregation is a multi-factorial as well as multi-step event, where many of the intrinsic 
and extrinsic factors simultaneously play a major role and result in protein aggregates with 
different ending states [45-47]. Intrinsic factors which are influential, include amino acid 
sequences, level of chemical modifications and the physiochemical nature of the protein. For 
example, a recombinant protein with a higher number of negative charge residues (Asn and 
Glu) is more soluble than a protein with a higher number of aromatic amino acids (Phe, Tyr, 
and Trp) expressed in E.coli [48]. Chemical modifications, which includes oxidation, 
deamination in the amino acid side chain and peptide bond cleavage often negatively affects 
the physical properties such as hydrophobicity, secondary and/or tertiary structure, 
thermodynamic parameters and thereby changing the protein’s solubility profile [49, 50]. 
Amino acid side chain oxidation, particularly Cys, Met, Trp, and His, is one of the major 
degradation pathways for proteins [51-53]. The level and specificity of the oxidation mainly 
depend on the way they are generated [54]. Though amino acid asparagine (Asn) being 
especially significant for deamination, it has been shown that the Gly in the C-terminal 





Extrinsic factors like the composition of buffers, pH, extreme temperatures, freeze-thaw or 
various mechanical stresses (pumping, shaking, stirring, etc), adsorption to air-liquid and 
solid-liquid often cause protein aggregation. The anionic condition of the buffer strongly 
modulates the protein solubility and aggregation. For example, the phosphate ion presents in 
phosphate buffer may interact with positively charged amino acid residues on the protein 
surface and diminish their electrostatic repulsive effect, leading to protein aggregation [56]. 
Solution pH is an important factor regulating protein solubility as well as aggregation. 
Solution pH determines the net charge of a protein as well as the charge type (positive and 
negative), thereby affecting the electrostatic interaction between the protein molecules [57]. 
On the other hand, extreme temperatures or mechanical stresses may cause partial/complete 
denaturation of protein and result in protein aggregation with undefined biophysical and 
biochemical properties [58]. This process generally produces irreversible aggregation. 
Aggregates can even form under the condition which is thermodynamically favoured for a 
native state, without any external stress [59]. 
 
1.4.2 Classification of protein aggregates 
From a morphological standpoint, protein aggregates are classified into two major groups: 
amyloid fibrils and amorphous aggregates. Amyloid fibrils are unique linear assemblies’ of 
aggregates that contain an ordered cross beta-sheet structure and are generally insoluble [60]. 
Unlike amyloids, amorphous aggregates are randomly formed without any defined ordered 
intermolecular interaction. Amorphous aggregates can be formed through simple 
hydrophobic, Van der Waals interaction and/or electrostatic interaction [61]. These 
aggregates, particularly smaller one are often form reversibly. On the other hand, covalent 
aggregates that formed through intermolecular disulfide cross-linking, are irreversible in 
nature. Additionally, most large or insoluble aggregates, even without covalent linkage are 
irreversible. 
Size is perhaps the most common parameter used to classify protein aggregates. Many terms 
are being used to define the aggregates’ size. However, those naming systems are often 
confusing, because different research groups use different terms to indicate the same size 
aggregates. In 2012, Narhi et al. proposed quantitative categories, such as >100µm (previous 




(sub-micron), and < 100nm or nanometer size aggregates, which were previously defined as 
oligomers or soluble aggregates (Table 1.1) [62].  
In aggregates, protein molecules may get associated into their native conformation to unfolded 
conformation, and anything in between the both.  Aggregates conformation includes the 
properties of secondary and tertiary structure, stability and surface hydrophobicity. Based on 
these characteristic feature aggregates are classified as  “native,” “partially unfolded,” 
“misfolded,” “inherently disordered,” “unfolded,” or “amyloid [62]. 
Chemical modification in the protein molecules is one of the critical factors for aggregate 
formation, thereby aggregates are often characterized based on the chemical modification. 
Covalent cross-linking is one of the best example that results in irreversible protein 
aggregation. Aggregates may contain reducible intermolecular or intramolecular disulfide 
cross-linking. On the other hand, non-reducible chemical crosslinking includes thioether and 
dityrosine covalent bonds [62]. 
 
1.5 How the immune system responds against protein aggregates 
The immune system, a complex biological process, responds differently against different 
aggregate types, therefore, the exact mechanism is yet to be fully understood. The biophysical 
and biochemical nature of the protein aggregates, including size, morphology, stability and 
their surface charge properties greatly influences their immunogenicity. It is now becoming 
increasingly clear that all type of aggregates is not equally immunogenic. However, the 
defensive mechanism against aggregated proteins, as like other pathogens, is mainly 
conducted by two different but interconnected subsystems, where innate responses provide 
the first line defences and adaptive immune responses provide long-term and much stronger 
defences.  
 
1.5.1 Innate response 
The innate immune response protects the organism, when the adaptive response is not 
stimulated, by preventing the immediate spread of the pathogen throughout the body. The 
prime component of innate immune response is the phagocytic cells (neutrophils, 
macrophage), natural killer cells, cytokines, and the member of the complement system. 




for the deposition of beta-amyloid in Alzheimer patients [63], and activate the innate immune 
cells embedded in the tissue [64, 65]. It has also been reported that aggregated protein in beta-
amyloid plaque increased the production of TNF-α through Toll-like receptor 2 and 4 (TLR2 
and TLR4) stimulation [66]. TLRs are a family of transmembrane receptors, which recognize 
the pathogen-associated molecular patterns (PAMPs), and thereby known as a pattern 
recognition receptor [67, 68]. Widely known PAMPs is the bacterial lipopolysaccharide 
(LPS), an outer membrane component of gram-negative bacteria, which initiate the innate 
immune response by activating the TLR4 [69]. Similarly, the aggregated protein, for example, 
the monoclonal antibody aggregates, activate the TLR2 and TLR4 and induce the secretion of 
inflammatory cytokine [70].  Moreover, the antibody aggregates also involved in Fc gamma 
(Fcγ) receptor-mediated innate immune response. It has been shown that antibody aggregates 
crosslink the Fcγ receptor on the antigen-presenting cells (APCs) more efficiently than a 
monomeric counterpart [71]. In another study, using surface plasmon resonance (SPR) 
showed that the dimer and multimers of  IgG1 monoclonal antibody bind more strongly with 
the Fcγ receptor than that of monomeric IgG1 [71]. The complement system is one of the 
major defences in innate immune responses, which can be initially activated by any of three 
pathways (alternative, classical, and lectin) [72]. During the immune response against a 
foreign antigen, the complement protein binds or fixes with the antigen-antibody complex. 
Experimental studies reported that the aggregated IgG more efficiently binded and activated 
the C1 protein (the first binding protein in the classical pathway) than that of monomeric IgG 
[73]. Similarly, the antivenoms IgG that forms dimers and polymers in the presence of 
preservatives (thimerosal and/or phenol) induce a higher complement activation [74].  
 
1.5.2 Adaptive response 
Unlike the innate immune response, the development of adaptive immunity requires a longer 
time as this system of response uses an immunological memory to learn about the threat and 
enhance the immune response accordingly. The adaptive immune response follows a series of 
sequential intra and extracellular events and ultimately activates antigen-specific antibody-





a) The mechanism of aggregates mediating T-cell dependent B-cell activation 
Generation of effective anti-drug antibodies (ADAs) response against a therapeutic protein 
through the activation of T-cells are termed a thymus-dependent or a T-cell dependent (TD) 
pathway. This T-cell dependent B-cell activation requires three major signaling pathways: 
I) Activation of T-cells by antigen-presenting cells (APCs) 
II) Interaction of protein antigen with B-cell receptors (BCRs) 
III) Interaction of toll-like receptors of B-cells with foreign protein moieties  
I) Activation of T-cells by antigen-presenting cells (APCs): Antigen-presenting cells 
(APCs) play the master role for T-cell activation. Firstly, antigen processing is induced by 
professional antigen sensing dendritic cells (DCs) in the periphery [75]. Protein aggregates 
have a different molecular pattern, thereby APCs, such as DCs, follow distinct uptake 
pathways (Figure 1.4). Protein aggregates may follow a pathogen-associated molecular 
pattern (PAMP) and be efficiently uptaken by pattern recognition receptors, known as toll-
like receptors (TLRs). Alternatively, either small or large aggregates of protein can often 
mimic the ‘immune complex’, particularly the IgG aggregates, and hence increase the binding 
with FcγR [76]. Finally, aggregated proteins are internalized through receptor-mediated 
phagocytosis and digested by lysosome and produce small linear peptides, which are then 
bound with MHC-II molecules and are presented on the cell surface molecules. In addition, 
the co-stimulatory molecules (CD80 and CD86) are also expressed. After antigen encounters 
and processing by APCs, systematically they migrate to lymph nodes, particularly in the T-
cell zone [77]. Here they perform a thorough scan and find the appropriate T-cells, whose 
receptors are perfectly fit with antigenic peptides just like in a ‘key-lock’ manner (Figure 
1.5). Finally, the antigen primed activated T-cells move to follicles, where B-cells reside. 
II) Interaction of protein antigen with B-cell receptors (BCRs): The protein antigens first 
migrate to secondary lymphoid organs, such as lymph nodes through lymphatic vessels, where 
they are filtered through a draining system and thereby become accessible to B-cells. Next, 
protein antigens are scanned by B-cells, and the B-cell receptors (BCRs) bind with specific 
antigens, resulting in the activation of B-cells (Figure 1.5). Like APCs, the antigen bind BCRs 
which are internalized by activated B-cells and finally expressed as MHC-II associated 




cells proliferation and differentiation. But they require a second signal which comes from the 
activated helper T-cells primed with the same antigen (Figure 1.5). To do so, after BCR-
antigen interaction, B-cells migrate to the border of the B/T-cell zone, where the peptide 
associated MHC-II of the B-cell interacts with TCRs of the T-cell. At the same time CD40 
ligand (CD40L) of the T-cell bind with the CD40 receptor of the B-cells.  
III) Interaction of toll-like receptors of B-cells with foreign protein moieties: In addition 
to those two signals, it has been reported that a third signal is required to finalize the B-cells 
maturation. This third signal is accomplished by the antigenic epitopes of the foreign proteins 
that bind with toll-like receptors (TLRs), which reside on the B-cell. 
b) The mechanism of aggregates mediating T-cell independent B-cell activation 
T-cell independent B-cell activation and antibody production strongly requires the B-cell 
receptors (BCRs) cross-linking. B-cells of the marginal zone of the spleen (MZ B-cells) and 
B-1 cells play a major role in the TI pathway, as they can generate a rapid response and do 
not involve affinity maturation. The large protein aggregates consist of at least ten repetitive 
arrays of monomers can initiate the TI pathway by cross-linking the BCR residing on B-1 or 
MZ B-cells (Figure 1.6) [78]. However, the large protein aggregates often fail to induce TI, 
this is because of their irregularly and rigidly ordered structure [79]. The B-cells proliferations 
then require a second signal and it is hypothesized that TLR on the B-cell (particularly B-1 
cells) provide the second signal by binding with PAMP motifs on the aggregates. There are 
two distinct subgroups of TI antigens, namely, TI-1 and TI-2 antigens. TI-1 antigen, like 
bacterial lipopolysaccharides, have an intrinsic property to initiate the B-cells proliferation 
and differentiation without T-cells help and even without any BCRs specificity. In this case, 
TLRs play a major role. On the other hand, TI-2 antigens are generally differentiated by their 
highly repetitive epitope structure. For example, the surface polysaccharide on encapsulated 
bacteria. They can activate the downstream signalling of the B-cell by cross-linking the BCRs. 
In such a case the immature B-cells are anergized and only mature B-cells can activate. That 
may explain why children up to 5 years are not capable of producing effective antibodies 
against polysaccharide antigens, as the majority of their B cell population is immature. 
One of the major differences between TD and TI pathways is that the TI pathway 




happen that produces IgG. Most of the TI antigens do not generate immunological memory as 
TD dependent antigens. 
1.6 Anti-EGFR single domain antibody (VHH) 
Epidermal growth factor receptor (EGFR) is a receptor of the tyrosine kinase family that 
efficiently regulates cell growth, differentiation and proliferation by binding with natural 
ligands, called epidermal growth factor (EGF) [80]. However, the over expressed or mutated 
EGFRs are often been characterized in cancerous cells, such as lung, breast and nail cancer 
[80]. Monoclonal antibodies (mAbs), such as cetuximab and panitumumab, targeting EGFR 
have demonstrated their activity against several cancer types [81, 82]. These mAbs bind with 
the extracellular domain of the EGFR, inhibit the binding of growth factor associated ligands, 
including epidermal growth factor (EGF) and transforming growth factor-alpha and 
subsequently block the downstream signalling cascade. However, their relatively large size 
often decrease their efficient tumor penetration.  
Single domain antibody (VHH), often referred to as a nanobody, is an engineered fragment 
antibody developed from a unique class of antibodies called heavy chain only antibody 
(HcAb) [83]. Camelidae (camels, llamas and dromedaries) naturally produces HcAb and 
unlike conventional mammalian IgG antibody, this class of antibody naturally devoid the light 
chain and CH1 domain, so-called heavy chain only antibody (HcAb) (Figure 1.7). As 
compared to conventional VH/VL antigen-binding interface, a single domain VHH itself holds 
three complementary determining regions (CDRs) and retain its antigen specificity [83]. 
CDRs adopt a loop structure, where CDR3 found as a long loop structure (20~30 amino acids) 
that increase their ability to fit with the antigen surface and resulting in strong binding with 
the corresponding antigen. Moreover, this extended CDRs loop allows the antibody to bind 
the protein cleft/pocket, including the enzyme active site, which is not possible for a 
conventional antibody’s binding interface [84-86]. Their minimal size (~15 kDa) provides an 
efficient tumor penetration rate. Moreover, their cost-effective bacterial expression makes 
them an ideal antibody drug candidate. To date, three EGFR targeting VHH antibodies have 
developed: VHH-7D12, VHH-9G8 and VHH-Ega1. These VHHs have different CDRs and thereby 
bind different EGFR epitopes and regulate the downstream signalling. Among them, VHH-




monoclonal antibody cetuximab. On the other hand, VHH-9G8 binds to a region located 
between the EGFR extracellular domain II and domain III and thereby inhibits the receptor 
dimerization. However, due to their smaller size, it is expected that VHH antibody will be less 
immunogenic but yet to be investigated.  
 
1.7 Motivation 
It is well acknowledged that protein aggregate causes unwanted immunogenicity. Several 
recent studies have reported the relationship between the aggregate’s properties, particularly 
the aggregate’s size, and the strength of the immune responses. However, some of the 
conclusions remain a matter of debate. It is now becoming increasingly clear that amorphous 
aggregates possess distinct biochemical and biophysical nature. In protein chemistry, 
amorphous aggregates, besides their size, are often characterized based on their conformation 
(native, misfolded, partially unfolded or completely unfolded), reversibility and also the type 
of chemical modifications. Therefore, I aimed at exploring the conformational and 
biochemical nature of the amorphous aggregates and investigated their immunogenic response 
in mice models, using anti-EGFR VHH antibodies, as a model of therapeutic protein. In 
addition, I aimed to determine the type of IgG and the T-cell immunological memory 
generated by anti-EGFR VHH aggregates and their long-term immunogenicity risk against the 












Figure 1.1: Factors that may influence the protein’s immunogenicity. Treatment, product, 
and patient-related factors that can impact upon the immunogenic potential of a bio-





Figure1.2: Schematic representation of the proposed two-wave mechanism of antigen 
presentation following subcutaneous injection of protein. (A) Protein antigens migrate to 
lymph nodes through lymphatic vessels and encountered by LN-resident DC cells, which 
provides the first wave of antigen presentation. (B) Protein antigen uptake by migratory DC 
and DC-antigen complex migrate to lymph nodes and creates a second wave of antigen 






















Figure 1.3: Protein aggregation pathway. In aggregates, individual protein molecules may 
get associated with different types and levels of intermolecular interaction. Protein aggregates 
may be formed with a defined ordered structure, called amyloid fibrils. Aggregates may also 
be formed under the complete denaturation of the monomeric protein, which are amorphous 
in nature and generally irreversible. Partial denaturation of protein molecules also influences 
the formation of the aggregates by increasing the intermolecular hydrophobic interaction. 
Depending on the solution condition these types of aggregates may reverse back to their initial 





Figure1.4: Aggregated protein antigen up uptake by antigen-presenting cells (APCs). 
Protein antigen can uptake by APC through receptor-mediated endocytosis or phagocytosis. 
Protein aggregates may uptake by pattern recognition receptor, known as toll-like receptor 
(TLR). Antibody aggregates may uptake by Fcγ receptors. (Figure adopted from Moussa et 



















Figure 1.5: T-cell dependent B-cell activation pathway. Recognition of antigen by B-cell 
receptors (BCRs) provides the first signal for B-cells activation. The second signal comes 
from the T-cells that are activated by the same antigens. Finally, antigen-binding with TLRs 





















Figure1.6: T-cell independent B-cell activation. In T-cell independent pathway, B-cells are 
activated by cross-linking of BCRs. Particularly Type 2 antigens activate the B-cells by BCRs 
cross-linking. Type 1 antigen binds with both the BCRs and TLRs and thereby activates the 
B-cells without T-cells help, which mainly produces IgM and some class-switching to IgG. 






Figure1.7: Generation of Single Domain Antibody. Camelidae (camels, llamas and 
dromedaries) naturally produces heavy chain only antibody (HcAb). Unlike conventional 
mammalian IgG antibody, this class of antibody naturally devoids the light chain and CH1 





Table 1.1 Classification of protein aggregates (Narhi, L.O., et al., Classification of protein 
aggregates. Journal of pharmaceutical sciences, 2012. 101(2): p. 493-8)  
Category Classification 
Size <100 nm, 100–1000 nm (sub-micrometer), 
1–100 :m, >100 :m 
Reversibility Reversible, irreversible, dissociable, 
dissociable under physiological 




Native, partially unfolded, unfolded, 
inherently disordered, Amyloid 
Covalent 
modification 
Cross-linked, reducible cross-link, 
nonreducible cross-link, intramolecular 
modification, oxidation, deamidation, 
no modification 
Morphology Number of monomeric subunits, aspect 
ratio, surface roughness, internal 

















The immunogenicity of an anti-EGFR single 
domain antibody (VHH) is enhanced by misfolded 
amorphous aggregation but not by heat-induced 





Advances in biotechnology have paved the way for the use of recombinant therapeutic 
proteins [87]. However, protein aggregation may cause unwanted immunogenicity, which not 
only lessens the efficacy and safety of protein-based drugs [23] but can also hamper the 
function of endogenous proteins [5, 88]. This phenomenon has been coined ADAs (anti-drug 
antibodies) [89] and has been invoked in several clinical reports [90, 91]. For example, clinical 
studies have noticed that the risks of ADAs against human growth hormone (hGH) might be 
associated with the formation of aggregates [21, 22]. In vivo and in vitro immunological 
studies are also suggesting that protein aggregation can cause ADAs, as shown for human 
interferon-beta (INF-β) [92], factor VIII [93], and monoclonal antibodies (mAbs) [94]. 
Several studies have reported the relationship between aggregate’s structural and biophysical 
properties and immunogenicity. For example, though native-like structural factor VIII 
aggregates were immunogenic [93], the aggregates of the fully unfolded factor VIII were less 
immunogenic [95]. On the other hand, natively functional aggregates (according to dot 
blotting) of IgG mAbs generated by freeze-thaw or shaking are not immunogenic, but they 
turn immunogenic upon chemical modification, such as oxidation [96]. Similarly, oxidation 
of rhIFN-1a aggregates increased its immunogenicity [97]. 
Recent studies have reported a relationship between the strength of the immune response and 
the aggregate’s size [35, 37, 38] or the concentration [70], but some of the conclusions remain 
a matter of debate. For instance, in vivo mice experiments have shown that aggregates of mAb 
smaller than 100 nm sizes can generate a robust immune response [35]. Even few nanometers 
size protein’s aggregates have been reported as immunogenic [40]. However, other studies 
reported that mAbs that formed submicron aggregates between 0.1 and 1µm were the most 
immunogenic [37]. Amorphous aggregates are thus not equally immunogenic, and beside the 
aggregate’s size, other intertwined factors, such as the aggregate’s biophysical and 
biochemical nature, appear to affect a protein’s immunogenicity. 
The biophysical nature of protein amorphous aggregates has attracted interest from a 
protein chemistry viewpoint [98]. It is now becoming increasingly clear that amorphous 
aggregates can display distinctive features besides their size: they can be formed by the 




Furthermore, amorphous aggregates can be classified according to their sizes but also 
according to the reversibility of association, the formation of covalent intermolecular bonds, 
chemical modifications, and possibly morphologies [49, 62, 99]. The biophysical and 
biochemical nature of the aggregates will depend not only on the protein but also on the way 
they are generated [100] since aggregation can appear at any stage of the protein’s production 
[101]. 
In this study, we used an anti-EGFR VHH antibody (7D12) as a model of a therapeutic protein 
[102]. This is because several mutations in the epidermal growth factor receptor (EGFR) are 
associated with tumor formation [103], and full-length anti-EGFR mAbs, such 
as Panitumumab and Cetuximab [104], are being used in anti-cancer therapies. Due to its 
smaller size, anti-EGFR VHH is expected to overcome factors limiting the action of the full-
length anti-EGFR antibodies such as low tumor penetration, and above all, the high production 
cost [105]. In addition, ADAs has been reported for 1-5 % of patients using the full-length 
anti-EGFR mAbs [106]. On the other hand, because of its small size (MW < 15 kDa), anti-
EGFR VHH’s propensity to initiate an immune response is expected to be low, but this remains 
to be experimentally confirmed. 
2.1.2 Aim and Objective 
Here, we investigated the immunogenicity of a recombinant anti-EGFR VHH, with particular 
emphasis on the relationship between its in vivo immunogenicity and the biophysical and 
biochemical nature of the aggregates in four different aggregated states: two heat-aggregated 
states incubated at 65 °C and 95 °C, referred to as VHH-65 and VHH-95, respectively, and two 
misfolded aggregated states, isolated during the refolding / purification process, referred to as 
VHH-Ins and VHH-Mis. Biophysical and biochemical properties of those VHH aggregates were 
characterized using CD, DLS, SLS, size-exclusion chromatography and fluorescence 
spectroscopy. Further, we assessed their antigenic profile using Jcl:ICR mice model by 





2.2. Materials and Methods 
2.2.1 Protein expression and purification 
A synthetic gene encoding the anti-EGFR VHH was cloned into a pAED4 vector [107] at the 
endonuclease NdeI and EcoRI sites and transformed into E. coli BL21 (DE3) pLysS cell line. 
The cells were grown in Luria Bertani (LB) medium at 37 °C, and protein expression was 
induced with 1 mM isopropyl β- d-1-thiogalactopyranoside (IPTG) when the optical density 
(OD) of the culture reached 0.6 at 590 nm. The E. coli cells were harvested 6 hours after the 
addition of IPTG by mild centrifugation. The cells were lysed by sonication, and the cell lysate 
was centrifuged at 8000 rpm, 4 °C for 20 min. The precipitate was again sonicated twice using 
a cell lysis wash buffer (50 mM Tris-HCl pH 8.0, 1 % NP-40 (v/v), 0.1 % deoxycholic acid 
(w/v) and 5 mM EDTA). 
Inclusion bodies collected by sonication were dissolved in 6 M Guanidine hydrochloride, 10 
mM Tris-HCl, pH 8.5 (hereafter, buffer A), containing 10 mM dithiothreitol (DTT). After 
centrifugation at 8000 rpm, 4 °C for 20 min and filtration through a 0.2 µm filter, the samples 
were loaded onto an open Ni-NTA column (Qiagen, Germany). Subsequently, the column 
was washed thrice with the wash buffer (6 M urea, 10 mM Tris-HCl pH 8.5, 0.5 M NaCl), 
and VHH proteins were eluted with the elution buffer (6 M urea, 10 mM Tris-HCl pH 8.5, 0.5 
M NaCl, 0.5 M imidazole). After 15 hours of oxidation at room temperature, urea was 
removed by overnight dialysis against 10 mM Tris-HCl (pH 8.5) at 4 °C. The sample was then 
centrifuged at 8000 rpm, 4 °C for 20 min, and the supernatant was separated from the 
precipitate. Finally, the native proteins were purified from the supernatant fraction using a 
cation-exchange chromatography (Gigacap-s-650 M, Tosoh Bioscience, Tokyo, Japan), and 
the protein identities were confirmed by TOF/TOF TM 5800 (SCIEX, USA) (Figure 2.1). The 
purified native protein dissolved in Milli-Q (MQ) water was stored at -30 °C as a stock 
solution. The precipitate fraction was further used for the generation of VHH-Ins. 
2.2.2 Generation of the aggregates 
VHH-Ins: The precipitate fraction was dissolved in buffer A, and a second round of overnight 
dialysis was performed, and the sample was centrifuged in the same way as described above. 
The precipitate of the second dialysis was collected, dissolved again in buffer A, dialyzed, 




in 6 M guanidine hydrochloride with 10 % acetic acid solution, followed by overnight dialysis 
against Milli-Q water at 4 °C with a four-time exchange of the external solution. VHH-Ins was 
soluble in MQ-water and stored at -30 °C and kept as a stock solution. The aggregated samples 
were prepared just before the experiments by adding MQ-water and 5X PBS to the protein 
stock solution at a final protein concentration of 0.3 mg/mL in 1X PBS (137 mM NaCl, 2.7 
mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4, pH 7.4). 
VHH-Mis: The native anti-EGFR VHH protein was first dissolved in buffer A with 0.5 M DTT. 
After 2 hours of incubation at room temperature, the sample underwent dialysis overnight 
against MQ water at 4 °C. Afterward, the sample was centrifuged, and the precipitate was 
dissolved in buffer A and oxidized for 15 hours. After guanidine hydrochloride removal by 
overnight dialysis against 10 mM Tris-HCl (pH 8.5), the precipitate was collected by 
centrifugation. The precipitate was again dissolved in buffer A and the second round of 
dialysis and centrifugation was performed, as described above. The precipitate of the second 
dialysis was collected, followed by a third round of dialysis and centrifugation. Finally, the 
precipitate of the third dialysis was dissolved in 6 M guanidine hydrochloride with 10 % acetic 
acid solution, followed by overnight dialysis against MQ water at 4 °C (the external solution 
was changed four times). The VHH-Mis stock solution dissolved in MQ-water was stored at -
30 °C. The aggregates were generated in the same way as for VHH-Ins. A graphical 
representation of the VHH-Ins and VHH-Mis purification scheme is available as Figure 2.2. 
VHH-65 and VHH-95: The purified native anti-EGFR VHH protein was diluted to a 
concentration of 0.3 mg/mL in PBS (immunization buffer) and incubated at 65 °C for 45 min 
in a static heating block (VHH-65). For generating the fully denatured aggregates, 0.4 mg/mL 
of proteins in PBS were heated at 95 °C for 110 min as VHH are highly heat stable [108], and 
the precipitated proteins were collected after mild centrifugation (4000 ×g, 25 °C for 10 min). 
The supernatant concentration was measured using Nanodrop (Nanodrop-2000, Thermo 
Fisher Scientific, USA), and the precipitate was resuspended in a fresh PBS at a concentration 
of 0.3 mg/mL. Finally, the sample was passed through a 26 gauge syringe needle to produce 






2.2.3 Dynamic Light Scattering (DLS) and Static Light Scattering (SLS) 
DLS samples were prepared by diluting the protein stock solutions to 0.3 mg/mL in 20 mM 
Na-acetate buffer (pH 4.7) and PBS (pH 7.4). Afterward, 100 µL aliquot in a polystyrene 
cuvette was used for DLS measurement at 37 °C with automatic attenuation, run duration, and 
scan numbers. Dynamic light scattering (DLS) was measured using a Zetasizer Nano-S system 
(Malvern, UK). The aggregate’s size distributions were determined by computing the mean 
Z–average (Zave) of the hydrodynamic radius and polydispersity index (PDI). The 
hydrodynamic radius (Rh) was obtained from the size distribution using the Stokes-Einstein 
equation and averaged over three individual measurements. 
SLS was measured under the same conditions at a wavelength of 600 nm and 37 °C with an 
FP-8500 spectrofluorometer (JASCO, Tokyo, Japan) using a micro-cuvette with an optical 
path length of 3 mm. The final spectra were obtained by subtracting the corresponding buffer 
spectrum. 
2.2.4 High-Performance Size Exclusion Chromatography (HP-SEC) 
The formation of intermolecular SS bonds was investigated by high performance size 
exclusion chromatography (HP-SEC) using a Shimadzu LC-20AD HPLC equipment 
(SHIMADZU CORP, Japan). All VHH samples were prepared at a concentration of 0.1 mg/mL 
in PBS (pH 7.4) containing 6 M guanidine hydrochloride. For the reduced state, 0.5 M 
dithiothreitol (DTT) was used to cleave the disulfide bond. Before analysis, the samples were 
centrifuged (20,000 ×g, 20 min, 4 °C) and filtered with a 0.2-micron filter. 20 µL of the sample 
was loaded onto a TSK Gel 2000 SWXL column (Tosoh Bioscience, Tokyo, Japan) using 
PBS (pH 7.4) containing 6 M guanidine hydrochloride as a mobile phase at a flow of 0.5 
mL/min. The protein was detected by a fluorescence detector (RF-20A, SHIMADZU CORP, 
Japan) using an excitation wavelength of 295 nm and an emission wavelength of 345 nm for 
tryptophan. For experiments under the reduced conditions, the mobile phase was 
supplemented with 10 mM of DTT.   
2.2.5 Spectroscopic measurements 
Far-UV circular dichroism (CD) spectroscopy measurements were performed on a JASCO J-




were fixed to 0.3 mg/mL (20 M) in 20 mM Na-acetate buffer (pH 4.7) and PBS (pH 7.4). 
300 µL of the protein solution was placed in a 1 mm path-length quartz cuvette, and the spectra 
were collected in a continuous scanning mode from 260 to 200 nm wavelength. The spectral 
baseline was measured for each sample and subtracted to obtain the final spectrum. For each 
sample, the measurement was repeated three times. The secondary structure content was 
calculated by BeStSel [109]. 
Samples for tryptophan and 8-anilino-1-naphthalene-sulfonic acid (ANS) fluorescence 
measurements were prepared in the same way as for the CD measurements at a protein 
concentration of 0.3 mg/mL. For ANS fluorescence measurements, ANS was added to the 
solution at a final concentration of 20 µM and incubated at 25 °C for 5 min in the dark before 
measurement [110, 111]. The fluorescence measurements were performed on FP-8500 
spectrofluorometer (JASCO, Tokyo, Japan) and using a glass cuvette containing 200 µL of 
the sample at 37 °C. The tryptophan excitation and emission wavelength were set to, 
respectively, 295 nm and 345 nm, and the ANS fluorescence was measured with excitation 
and emission set to 380 nm and 480 nm, respectively. 
2.2.6 Binding activity by Surface Plasmon Resonance (SPR) 
The binding affinity of the anti-EGFR VHH to the extracellular domain of human EGFR 
(Abcam, UK) was carried out by surface plasmon resonance (SPR), as previously reported 
[112, 113]. In short, VHH of different concentrations was passed over a CM5 sensor chip 
(Biacore 2000, GE Healthcare, USA), where EGFR (20 μg/mL) was immobilized using amine 
coupling chemistry according to the manufacturer's guidance. All measurements were 
performed at a flow rate of 30 µL/min in 10 mM HBS-EP buffer pH 7.4, (10 mM HEPES, 
150 mM NaCl, 3 mM EDTA and 0.005 % surfactant P20) at 20 °C. We used VHH 
concentrations between 6.0 and 0.046 μg/mL. Data were fitted using the BIACORE 
evaluation software version 4.1, based on a 1:1 Langmuir binding model. 
2.2.7 Mice immunization and measurement of serum IgG level 
Young 4-week old adult female mice (Jcl:ICR; CLEA, Japan) were used in all experiments. 
The mice were accommodated on sterilized wood bedding at an ambient temperature 




dark cycle. In total, 30 mice were divided into six groups (n=5). Each group was treated with 
a different protein formulation, and a control group was treated with PBS only. 100 μL of 0.3 
mg/mL VHH protein (monomeric or aggregate) in PBS was injected subcutaneously once a 
week for up to six weeks. For monitoring the ADA (IgG) generation, tail-bleed (TB) samples 
were collected three days after each round of immunization. All of the experiments were 
performed in compliance with the Tokyo University of Agriculture and Technology (TUAT) 
and Japanese governmental regulations on animal experimentation. 
The generation of serum IgG antibodies was measured by standard sandwich ELISA method. 
For all samples, 96-well microtiter plates (TPP techno plastic product, Switzerland) were 
coated with 100 µL of 2.5 µg/mL native or misfolded anti-EGFR VHH in PBS (pH 7.4) and 
incubated at 25 °C overnight. Unbound proteins were removed by washing with PBS, and the 
plates were blocked with 1 % BSA at 37 °C for 45 min. Afterward, 150 µL of 50 times diluted 
serum samples were added onto the 1st well and followed by 3-fold serial dilution in 
subsequent wells containing 0.1 % BSA-PBS. After incubation at 37 °C for 2 hours and 
washing with PBS-0.05 % tween-20, 100 µL/well of goat anti-mouse Fc–specific HRP-
conjugated antibody (Thermo Fisher Scientific, USA) was added and incubated again at 37 
°C for 90 min. Unbound conjugates were removed by thoroughly washing with PBS-0.05 % 
tween 20, and OPD (o-phenylenediamine dihydrochloride) was added to the plates, which 
were incubated for 20 min for coloring. The reaction was stopped with 1 N sulfuric acid, and 
the plates were placed in a microplate reader for measuring the absorbance at 492 nm (SH-
9000 Lab, Hitachi High-Tech Science, Japan). Finally, we analyzed the data by a power fitting 
of OD 492 nm versus the reciprocal dilution of the antisera and used a cutoff of OD 492 nm 
= 0.1 above the background value to calculate the antibody titers. A previously developed 






2.3.1 Structural characterization 
We measured the biophysical properties of VHH in two buffers (Na-acetate buffer, pH 4.7 and 
PBS, pH 7.4) because the misfolded VHHs (VHH-Ins and VHH-Mis) were insoluble in PBS and 
soluble only at acidic pH, which enabled spectroscopic measurements. The final samples used 
in all of the experiments were prepared by adding MQ-water and 1M Na-acetate or 5X PBS 
stock buffer to the protein stock solution at a final protein concentration of 0.3 mg/mL in either 
20 mM Na-acetate buffer (pH 4.7) or 1X PBS (pH 7.4). The immunization experiments were 
all carried out using proteins in 1X PBS. 
Secondary structure: The secondary structure content was determined by far-UV CD (200–
260 nm). Both at pHs 4.7 and 7.4, the secondary structure content of the native VHH was 
typical of a β-sheeted protein in line with the X-ray crystal structure (PDB: 4KRL) (Figure 
2.3 A, B and Table 2.1). In addition, the thermal denaturation of VHH was cooperative and 
fully reversible, indicating a well-packed natively folded structure as reported previously 
[112] (Figure 2.4). By contrast, both the misfolded (VHH-Ins and VHH-Mis) and the 95 °C-
incubated VHH-95 were aggregated at pH 7.4, and CD could not be measured. At pH 4.7, 
where VHH-Ins and VHH-Mis could be solubilized, their spectra indicated a high helical content 
(Figure 2.3 A and Table 2.1), but no thermal denaturation was observed (Figure 2.4). Finally, 
the CD spectrum of VHH-65 at pH 7.4 was essentially the same as that of the native VHH. 
Tertiary structure: We assessed the tertiary structure of the VHHs using tryptophan and ANS 
fluorescence. The tryptophan fluorescence of the natively folded VHH showed strong intensity 
with an emission maximum at 345 nm, whereas the VHH-Ins and VHH-Mis emission was twice 
and thrice weaker than that of the native VHH, and with a blue shift of 4 nm, possibly reflecting 
a more hydrophobic environment resulting from the aggregation (Figure 2.5 and Table 2.2). 
This suggested that the tertiary structure of the two misfolded VHH formulations were non-
native, in line with the above far-UV CD results. The emission spectrum of VHH-65 at pH 7.4 
was slightly weaker than that of the native VHH (no blue shift), whereas that of VHH-95 was 




Next, we used ANS, which binds to exposed hydrophobic pockets and gives a strong 
fluorescence signal, to probe the nature of the tertiary structure [110]. The ANS fluorescence 
intensity of VHH-Ins and VHH-Mis was significantly stronger than that of the native VHH 
(Figure 2.6 and Table 2.2), suggesting that the proteins associated in a loosely-packed 
oligomer similar to a molten-globule [114] but with secondary structures distinct from the 
native one (Table 2.1). VHH-65 showed a marginal intensity increase, whereas VHH-95’s 
intensity was stronger than that of the native VHH but markedly weaker than the misfolded 
VHH. Altogether, the tryptophan and ANS fluorescence intensity (at PBS, pH 7.4) ranked, 
respectively, as follows: native VHH > VHH-65 > misfolded (VHH-Ins and VHH-Mis) > VHH-95, 
and misfolded (VHH-Ins and VHH-Mis) > VHH-95 > VHH-65 > native VHH. 
2.3.2 Aggregate sizes and intermolecular SS bonds 
We measured the sizes of the aggregates and the degree of aggregation by dynamic and static 
light scattering (DLS and SLS), respectively. The Zave hydrodynamic radius of the native 
VHH at pH 4.7 and 7.4 were, respectively, 2.07 ± 0.49 nm (PDI: 0.24 ± 0.06) and 3.54 ± 0.19 
nm (PDI: 0.22 ± 0.07) as expected for a monomeric VHH (Figure 2.7 and Table 2.3). In 
contrast, the Zave of VHH-Ins and VHH-Mis was above 1 m at pH 7.4. The Zave of VHH-95 
at pH 7.4 was 1722 ± 179 nm (PDI: 0.49 ± 0.09), and that of VHH-65 was slightly smaller at 
771.3 ± 26.30 nm (PDI: 0.15 ± 0.06). These aggregation trends were confirmed by static light 
scattering, which increases along with the particle size [115]. The scattering intensity of the 
native VHH was minimal, that of VHH-65 was marginally stronger and, those of the misfolded 
samples (VHH-Ins and VHH-Mis) and that of VHH-95 were the strongest (Figure 2.8 and Table 
2.3).  
The presence of intermolecular SS bonds was assessed by running the HP-SEC under 
denaturing conditions with and without reducing agent, dithiothreitol (DTT). Under both 
conditions, the native VHH and heat aggregated VHHs (VHH-65 and VHH-95) showed a single 
peak at around 15 min, corresponding to the molecular weight of the monomeric VHH (~15 
kDa) (Figure 2.9 A and B). On the other hand, the non-reduced VHH-Ins and VHH-Mis showed 
high molecular weight peaks, which essentially disappeared under the reducing conditions 
indicating the presence of intermolecular disulfide bonds in the unreduced VHH-Ins and VHH-




2.3.3 Binding activity 
The binding activities of the VHH to EGFR were measured using surface plasmon resonance 
(SPR). In line with previous reports [102], the native VHH bound to EGFR in a concentration-
dependent manner, further confirming the natively folded nature of our native VHH  (Figure 
2.10 A). The 65 °C incubated VHH-65 was weakly active, suggesting that a fraction of the 
VHH-65 are natively folded as suggested by CD (Figure 2.10 B) (A rough estimate based on 
anti-parallel beta-sheet content suggests that over 90 % of VHH-65 is folded; (Table 2.1). 
Contrastingly, the VHH-Ins, VHH-Mis and VHH-95 had no binding activity confirming that they 
are fully unfolded or misfolded (Figure 2.10 C, D and E). 
2.3.4 Effect of aggregate types on immune response  
The level of serum’s anti-VHH IgG (after 6 weeks of injection) measured by ELISA using the 
native VHH as the coating antigen (Figure 2.11 A) showed that the native VHH was scarcely 
immunogenic. The heat 65 °C incubated VHH-65 induced a moderate response (for three mice 
out of five mice). No immune response was observed for VHH-95, even after six injections 
(for four mice out of five mice). However, we observed that the misfolded VHHs were strongly 
immunogenic, even though the aggregates formed by the misfolded VHHs (VHH-Ins and VHH-
Mis) as well as the heat-induced VHH-95 had Rh> 1 micron according to DLS. Indeed, all of 
the five mice injected with VHH-Mis responded unambiguously and in VHH-Ins three out of 






There are growing concerns and evidence that the amorphous aggregation of therapeutic 
proteins can cause unwanted immunogenicity [57, 116, 117]. Amorphous aggregates can 
exhibit, besides their sizes, various biophysical attributes: the characteristics of the aggregates 
such as conformation, level of chemical modifications, molecular orientation, and possibly 
morphology, which can affect the immunogenicity of a protein [118].  
We thus sought to investigate the biophysical nature of the amorphous aggregates that increase 
the immunogenicity of the therapeutic protein. To this end, we characterized the biophysical 
properties and assessed the immunogenicity of VHH in four types of amorphous aggregates: 
VHH expressed in the inclusion body (VHH-Ins); a misfolded aggregate produced by miss-
shuffling the SS bonds of the HPLC-purified native VHH (VHH-Mis), which was used for 
mimicking the inclusion body fraction in a purified formulation; and two aggregates produced 
by heat denaturation at 65 and 95 °C and maintaining the native intramolecular SS bonds 
(VHH-65 and VHH-95, respectively). 
The native VHH in a monomeric and active form was barely immunogenic, even after six 
injections. By contrast, VHH-Ins and VHH-Mis, which formed intermolecular SS bonds and had 
secondary structure contents clearly distinct from that of the native VHH (Figure 2.3 A and 
B), were highly immunogenic. Tryptophan and ANS fluorescence suggested that VHH-Ins and 
VHH-Mis formed a loosely-packed, hydrophobic, globular aggregates (Figure 2.5, 2.6 and 
Table 2.2) [110, 119]. Their aggregates were soluble at acidic pH (pH 4.7) but formed large 
aggregates in PBS buffer (pH 7.4) (Table 2.3). The high immunogenicity of VHH-Ins and VHH-
Mis appears to be related to the scrambling of disulfide bonds. However, other factors such as 
side-chain oxidation [120] and the particle’s size distribution may influence their 
immunogenicity. In particular, aggregate’s size has been reported as an important factor 
contributing to the immunogenicity of a protein [118] but here we can only provide a 
qualitative description of such effect based on the samples’ photographs (Figure 2.13). 
Despite the presence of large aggregates and an aggregation propensity similar to that of 
misfolded VHH, strikingly, VHH-95 was not able to induce any antibody response. VHH-95 was 




were fully denatured. Finally, the higher PDI value of the VHH-95 formulation indicated the 
heterogeneous nature of the aggregates’ sizes (Table 2.3).  
The heat 65 °C aggregates (VHH-65) retained a native-like secondary and tertiary structure 
according to CD and fluorescence in line with the high (80 %) retention of its binding activity 
to EGFR (Figure 2.10 B), and it showed a higher immune response than the native VHH and 
the heat-denatured aggregates (VHH-95). In addition, let us note that VHH-65 contains 
aggregates with Rh~770 nm according to DLS and 80% of the proteins are monomer according 
to HP-SEC (Figure 2.14 and Table 2.3). These results suggest that native-like aggregates 
having the same secondary structure content as the native VHH, are responsible for increasing 
its immunogenicity. Such observation would agree with native-like aggregates of recombinant 
factor VIII being immunogenic [93] or with our previous experiments with proteins 
oligomerized into partially denatured aggregates using Isoleucine tag [40, 121]. 
Interestingly, ELISA experiments, in which we used the misfolded VHH (VHH-Ins) as a coating 
antigen indicated results similar to those obtained using the native VHH as a coating antigen 
(Figure 2.11 B). This observation is not well explained from a protein structural viewpoint, 
because the conformation of the misfolded sample is quite different from the native one [122-
125], as corroborated by the low content of anti-parallel β-sheets in the misfolded VHHs, which 
turned into  parallel β-sheets,-helices, and loops as assessed by CD and BeStSel (Table 2.1). 
Though speculative, one rationale for our observation would be that the misfolded protein 
conserves a native-like epitope structure. A second hypothesis would be that the native VHH 
denatures when plated on the ELISA plates. To this regard, the long term immunological 
experiments where the misfolded VHH produced a long term memory (i.e. IgG as well) against 
the native VHH (Figure 2.12) suggests that antibodies were generated against natively 
structured epitopes supporting the first hypothesis.  
Finally, for the purpose of discussion, let us recall some possible molecular mechanisms that 
might stand behind the immunogenicity increase through the aggregation of a protein. It is 
now widely recognized that aggregation mediated immune response may occur either through 
a T cell-dependent or independent pathway [116, 126]. T cell-independent activation of B 
cells requires a high concentration of antigens leading to B cell receptor (BCR) cross-linkage 




a T cell-dependent pathway, which is most likely in our case because of the long term 
immunological memory (Figure 2.12), aggregates will also induce a BCR cross-linkage, 
which will provide the first signal for activating the B cells, the second one being T Cell 
recognition [116, 127]. Additionally, it has recently been shown that aggregated antibodies 
may activate dendritic cells, which in turn induces a T cell-dependent activation of B cells 
[94], such scheme may provide a further rationale for the production of IgG and of the long 
term immunological memory. To date, we note that the generation of long term memory by 
aggregated proteins may not occur in transgenic mice tolerant for the antigen protein, as 
reported for rhINF-β [128].  
2.5. Conclusions 
Accidental aggregation of therapeutic proteins is the focus of much attention by drug 
regulatory agencies and biopharmaceutical companies as it may cause severe side effects in 
the form of undesired immunogenicity and the generation of ADAs. Here, we systematically 
showed that immunogenicity of a protein’s aggregate with hydrodynamic radii of ~2 µm 
(according to DLS) will exhibit different immunogenicities depending on their biochemical 
(intermolecular SS bonds) and biophysical nature (folded/unfolded). As such, this study is 
expected to pave the way toward a deeper understanding of the mechanisms underlying the 








Figure 2.1: Molecular weight by MALDI-TOF. Protein identities were confirmed by 
MALDI-TOF mass spectroscopy using a TOF/TOF TM 5800 machine (SCIEX) (A) Native 










Figure 2.2: Schematics and gel analysis of the VHH preparation. (A) Schematic of the VHH 
fractions. The VHH fractions used in the experiments are boxed in red. As in previous reports, 
the native VHH was isolated from the 1st supernatant and purified by ion-exchange 
chromatography. VHH-Ins is the precipitate obtained after three rounds of precipitation. (B) 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) of the fractions. 
+BME and –BME indicate, respectively, the presence (reducing condition) and absence (non-


























Figure 2.3: Secondary structure content VHH formulations: The secondary structures were 
analyzed using far-UV CD region (200–260 nm) at a protein concentration of 0.3 mg/mL at 
37 °C in 20 mM Na-acetate buffer, pH 4.7 (A),  and in PBS, pH 7.4 (B). Three accumulations 
were taken for each measurement and the final spectra were obtained by subtracting the 







Figure 2.4: Circular dichroism (CD) spectra of native and misfolded VHH. Protein samples 
were prepared at a concentration of 0.3 mg/mL in 20 mM Na-acetate buffer (pH 4.7) and PBS 
(pH 7.4). CD spectrum of the native protein (A) in acetate buffer at temperatures from 15 °C 
to 80 °C (B) reversibility measurement by cooling from 80 °C to 15 °C in acetate buffer (C) 
in PBS, from 15 °C to 80 °C and (D) reversibility by cooling from 80 °C back to 15 °C, 
measured in PBS. CD spectrum (E) of VHH-Ins in acetate buffer measured at temperatures 
from 15 °C to 80 °C (F) VHH-Mis in acetate buffer from 15 °C to 80 °C. Line symbols are 
explained within the panels. At both buffers, the thermal denaturation of native VHH was 
cooperative and fully reversible, up to 80 °C as measured, indicating a well-packed natively 
folded structure. No thermal denaturation was observed for misfolded VHH (VHH-Ins and VHH-

























Figure 2.5 Characterization of the tertiary structures by tryptophan. Tryptophan 
fluorescence intensity were measured at a protein concentration of 0.3 mg/mL at 37 °C. 
Tryptophan fluorescence intensity spectra (A) in 20 mM Na-acetate buffer, pH 4.7, (B) in 
PBS, pH 7.4. Three accumulations were taken for each measurement and the final spectra 
were obtained by subtracting the corresponding buffer spectrum. Line symbols are explained 




























Figure 2.6: Characterization of the tertiary structures by ANS. 8-anilino-1-naphthalene-
sulfonic acid (ANS) fluorescence intensity were measured at a protein concentration of 0.3 
mg/mL at 37 °C. ANS fluorescence intensity spectra (A) in 20 mM Na-acetate buffer, pH 4.7, 
(B) in PBS, pH 7.4. Three accumulations were taken for each measurement and the final 
spectra were obtained by subtracting the corresponding buffer spectrum. Line symbols are 




























































 Figure 2.7 Aggregate’s sizes by Dynamic Light Scattering (DLS). DLS measurements 
were performed at a protein concentration of 0.3 mg/mL at 37 °C. DLS spectra of the size 
distribution number (%) (A) in 20 mM  Na-acetate buffer, pH 4.7 and (B) in PBS, pH 7.4. 


























Figure 2.8: Degree of aggregation by Static Light Scattering (SLS). The intensity-based 
aggregate size was measured at 600 nm by SLS at a protein concentration of 0.3 mg/mL at 37 
°C (A) in 20 mM Na-acetate buffer, pH 4.7 and (B) in PBS, pH 7.4. (C) Comparative analysis 
of SLS intensity (a.u) and DLS Zave (nm) of the different aggregate formulation of anti-EGFR 
VHH in PBS. Three accumulations were taken for each measurement. Line symbols are 































































Figure 2.9: High-performance size exclusion chromatography (HP-SEC) analysis of the 
oligomerization state. Samples for size-exclusion chromatography in a denatured condition 
were prepared at a protein concentration of 0.1 mg/mL in PBS (pH 7.4) supplemented with 6 
M guanidine hydrochloride. 20 µL of the sample was used for the HP-SEC analysis in a non-
reducing (A) and a reducing (B) condition. Gray, black, and dark black triangles indicate the 














































Figure 2.10. Binding activity to EGFR by Surface Plasmon Resonance (SPR). Epidermal 
Growth Factor Receptor (EGFR) extracellular domain (20 μg/mL) was immobilized on a CM5 
sensor chip. Binding activity of anti-EGFR VHHs in (A) native (B) VHH-65 (C) VHH-Ins (D) 
VHH-Mis and (E) VHH-95 conditions were analyzed at concentrations between 6 µg/mL and 


























Figure 2.11: Anti-VHH antibody (IgG) titer assayed by ELISA. IgG detection by ELISA 
was performed using the tail bleeding (TB) sera, after six doses of subcutaneous injection. 
Each circle indicates the individual mice titer (total of five mice in each group) and the bars 
show the average titer calculated by excluding the outliers. The number of mice in each group, 
as well as those used to calculate the average, is mentioned in parenthesis. IgG titer measured 








































































Figure 2.12: Long-term IgG response and immunological memory. (A) Long-term serum 
IgG and immunological memory of VHH-Ins immunized mice (B) Long-term serum IgG and 
immunological memory of VHH-65 immunized mice and (C) Long-term serum IgG and 









Figure 2.13: Microscopic images of VHH formulations. Representative microscopic images 
of native VHH, VHH-65, VHH-95, VHH-Ins and VHH-Mis that were used for immunization. The 
images were taken by an inverted microscope (ECLIPSE Ts2-FL, Nikon, Tokyo, Japan) using 
a 40x magnification. Note that the size of the aggregates presented here may not be of 


















Figure 2.14. HP-SEC analysis of the oligomerization state. HP-SEC was performed to 
analyze the monomer and small oligomers that are present in the VHH formulations. All of the 
five VHH formulations were centrifuged at 20000 xg for 20 minutes and the supernatant 
concentration was measured by Nanodrop. Finally, 20 µL of the supernatant sample was used 
for HP-SEC analysis using PBS (pH 7.4) as a mobile solution and a flow rate of 0.5 mL/min. 
Protein elution was detected by a fluorescence detector (RF-20A, SHIMADZU CORP, Japan) 
using an excitation wavelength of 295 nm and an emission wavelength of 345 nm, specific 
for tryptophan residue. Line symbols are explained in the panel. Note that after centrifugation 






Table 2.1. Secondary structure content by BeStSel 




parallel (%) turn (%) others 
(%) 
Native 4.7 1.3 41.9 0.0 11.1 45.7 
7.4 1.3 41.4 0.0 11.2 46.1 
VHH-Ins 4.7 5.3 9.7 11.2 12.9 60.8 
7.4 NS* NS* NS* NS* NS* 
VHH-Mis 4.7 5.3 17.7 9.0 11.4 56.6 
7.4 NS* NS* NS* NS* NS* 
VHH-65 4.7 NM** NM** NM** NM** NM** 
7.4 0.0 38.9 3.9 12.4 44.8 
VHH-95 4.7 NM** NM** NM** NM** NM** 
7.4 NS* NS* NS* NS* NS* 
*NS= No Signal due to the formation of large aggregates 





Table 2.2. Tryptophan and ANS fluorescence intensities 
Sample Trp fluorescence (a.u) 
at 345 nm 
 ANS fluorescence (a.u) 
at 480 nm 
pH 4.7 pH 7.4 Fluorescence 
shift (nm) 
 pH 4.7 pH 7.4 
Native 3102 ± 35 3140 ±  53 0  9 ± 3 7 ± 2 
 
VHH-Ins 1676 ± 80 
 
1372 ± 187 4 **  834 ± 50 459 ± 27 
 
VHH-Mis 894 ± 127 
 
1025 ± 46 
 
4 **  587 ± 84 438 ± 80 
 
VHH-65 NM* 2716 ± 165 0  NM* 102 ± 7 
 
VHH-95 NM* 894 ± 170 4 **  NM* 298 ± 24 
 






Table 2.3. Aggregate’s sizes by DLS and SLS 
Sample pH  DLS  SLS 






4.7 2.1 ± 0.5 0.24 ± 0.06 1.7 ± 0.1 8.9 ± 1.4 
7.4 3.5 ± 0.2 0.22 ± 0.07 2.1 ± 0.1 28.0 ± 0.5 
VHH-Ins 4.7 30.4 ± 1.0 0.36 ± 0.01 10.9 ± 1.5 239.0 ± 19.2 
7.4 1846.5 ± 409.4 0.27 ± 0.12 1166.4 ± 324.5 7877.5 ± 264.2 
VHH-Mis 4.7 20.0 ± 0.2 0.30 ± 0.01 8.1  ± 1.4  119.0 ± 2.0  
7.4 1951.7 ± 373.3 0.49 ± 0.08 1135.8 ± 269.0  6134.7 ±  84.6 
VHH-65 7.4 771.3 ± 26.3 0.15 ± 0.06 571.6 ± 25.0 2477.0 ± 115.0 
VHH-95 7.4 1722.3 ± 180.0 0.49 ± 0.09 1100.7 ± 258.1 8400.1 ± 454.1 
*Mean Z-average hydrodynamic radius 
** Hydrodynamic radius (Rh) calculated from the number mean. Errors indicate the standard      














Immune response with long-term memory triggered 
by amorphous aggregates of misfolded anti-EGFR 
VHH-7D12 is directed against the native VHH-7D12 






Breakage of the immune tolerance and the consequent production of anti-drug antibodies 
(ADAs) is becoming a major concern in protein drug's safety and usage [88, 129]. Clinical 
observations indicate that ADAs can reduce the hemostatic efficiency of factor VIII by 
approximately 30% in haemophilia A patients [2, 130]. Likewise, antibodies developed 
against recombinant human acid-alpha glucosidase (rhGAA) can adversely impact their 
efficacy in the treatment of Pompe disease [131]. Protein aggregation has long been suspected 
of provoking accidental immunogenicity of protein drugs, resulting in ADAs [12, 23, 116]. 
Besides clinical observations, where protein aggregates are rarely monitored and 
characterized, several experimental studies using human interferon-beta (INF-β) [92], factor 
VIII [132], growth hormones [133], and monoclonal antibodies (mAbs) [94, 134] have shown 
that aggregates may indeed generate ADAs. 
The increased immunogenicity of protein aggregates is not fully understood, but it is 
speculated that their multiple repetitive epitopes act like a pathogen-associated molecular 
pattern (PAMP), which are recognized by pattern recognition receptors (toll-like receptors, 
TLRs) residing on antigen-presenting cells (APCs) [116] and increase the expression of 
peptide associated MHC-II molecules [94, 135]. In another hypothesis, aggregated proteins, 
particularly monoclonal antibody aggregates, can act like an ‘immune complex’,  thereby 
enhancing the FcγR mediated APCs internalization and processing [76]. From a protein 
conformational standpoint, it has been shown that aggregated protein potentially enhanced the 
expression of new  B-cell epitopes and facilitating the IgG generation  [135]. The aggregated 
proteins may be natively folded, misfolded, partially unfolded, or completely unfolded [59], 
which will presumably expose different epitopes and generate ADAs with different 
specificities [95]. 
Engineered antibody and antibody fragments are a fast-growing class of therapeutic proteins 
[8, 136-138]. Single domain antibody (VHH) is a unique class of antibody, and unlike full-
length antibody, it consists of a single variable heavy domain containing three 
complementarity determining regions (CDRs) [83]. VHH adopts an Ig fold, and its framework 
regions have high sequence and structure similarities, but the sequence and conformation of 




they adopt a loop structure that increases their ability to fit the antigen surface resulting in a 
strong binding with the corresponding antigen [139]. ADAs targeting the CDRs are expected 
to inhibit VHH's ability to bind to the antigen and thus correspond to neutralizing ADAs, which 
are the most critical ones from a clinical perspective. ADAs that bind to the framework regions 
of the VHH are anticipated to be non-neutralizing, but they are susceptible to show cross-
immune reactivity with analogous VHHs. Since the framework regions' sequences and 
structures of the VHHs are very similar to each other, it is worth exploring the nature of ADAs 
specificity and their relationship with long-term immunogenicity risk. 
3.1.2 Aim and objective 
In our previous study, we reported the immunogenicity of an anti-EGFR VHH-7D12 that 
increased by the formation of amorphous aggregates generated by miss-shuffling of its SS 
bonds (VHH-Mis) [140]. Here, we sought to investigate further the nature of the immune 
response generated by VHH-Mis by assessing its specificity against the CDRs/framework 
regions. To this end, we immunized the mice with VHH-Mis and examined its effect on the 
immune response against its native self (native VHH-7D12) and an analog (native anti-EGFR 
VHH-9G8), whose framework region is virtually identical to that of VHH-7D12, but the CDRs 
are different [141]. Furthermore, we assessed the generation of T-cell immunological memory 
by analyzing the cell surface CD (cluster of differentiations) marker. Our findings provide a 
deeper understanding of the specificity of the immune response and long-term 




3.2 Materials and Methods 
3.2.1 Protein expression and purification 
A pAED4 vector [107] containing a synthetic gene that encodes anti-EGFR VHH-7D12 or 
VHH-9G8 was transformed into E. coli BL21 (DE3) pLysS cell lines and grown in Luria 
Bertani (LB) medium at 37 °C. Protein expression was induced with 1 mM isopropyl β-d-1-
thiogalactopyranoside (IPTG) when the optical density (OD) of the culture reached 0.6 at 590 
nm. Six hours after induction of protein expression, the cells were harvested by mild 
centrifugation (8000 rpm for 20 min at 4 °C). After sonication, the protein was purified by Ni-
NTA (Qiagen, Germany), followed by ion-exchange chromatography (Gigacap-s-650 M, 
Tosoh Bioscience, Tokyo, Japan) according to our previously reported protocol [140]. Protein 
identities were then confirmed by MALDI-TOF mass spectrometry (autoflex speed 
TOF/TOF, US) (Figure 3.1), and the purified proteins dissolved in Milli-Q (MQ) water was 
kept at -30 °C as a stock protein solution. 
 
3.2.2 Generation of misfolded VHH-7D12 aggregates (VHH-Mis) 
Misfolded anti-EGFR VHH-7D12 (VHH-Mis) was generated according to our reported protocol 
[140]. In short, the native VHH-7D12 protein was first dissolved in 6 M guanidine 
hydrochloride and 10 mM Tris-HCl (pH 8.5), buffer A, and reduced with 0.5 M dithiothreitol 
(DTT) by a 2-hour incubation at room temperature. The sample was dialyzed overnight 
against MQ water at 4 °C and centrifuged. The precipitate was collected and dissolved in 
buffer A and oxidized for 15 hours at 25 °C. The guanidine hydrochloride was removed by 
again overnight dialysis against 10 mM Tris-HCl (pH 8.5). The precipitate collected by 
centrifugation was again dissolved in buffer A and underwent a second iteration of dialysis 
and centrifugation. Similarly, after a third iteration, the resulting precipitate was dissolved in 
6 M guanidine hydrochloride with 10% acetic acid solution and dialyzed overnight against 
MQ water at 4 °C. Finally, the supernatant containing misfolded VHH-7D12 was stored at -30 
°C as a VHH-Mis stock solution. The VHH-Mis sample was freshly prepared just before each 
set of experiments by adding the required amount of MQ-water and 5X PBS buffer to the 
VHH-Mis stock solution to a final buffer condition of 1X PBS. A graphical representation of 





3.2.3 Circular dichroism (cd)  
Far-UV circular dichroism (cd) spectroscopy measurements were performed at a protein 
concentration of 0.3 mg/mL (20 M) in PBS (pH 7.4) using a JASCO J-820 
spectropolarimeter (JASCO, Tokyo, Japan) at 37 °C. 300 µL of the protein solution was 
placed in a 1 mm path-length quartz cuvette, and the spectra were collected in a continuous 
scanning mode from 260 to 200 nm wavelength. For each measurement, three accumulations 
were considered, and the final spectrum was obtained by subtracting the corresponding buffer 
spectrum. 
3.2.4 Dynamic light scattering (DLS)  
Dynamic light scattering (DLS) properties of both native and misfolded VHHs were measured 
at 37 °C with a Zetasizer Nano-S system (Malvern, UK) in PBS (pH 7.4) at a final protein 
concentration of 0.3 mg/mL using a 100 µL-polystyrene cuvette. The reported hydrodynamic 
radii (Rh) are the average of three or more individual readings. 
3.2.5 Mice immunization  
4-week old female mice (Jcl: ICR; CLEA, Japan) were immunized by subcutaneous injection 
of the samples according to the following protocol (Figure 3.2B). 100 µL of VHH-Mis at a 
concentration of 0.3 mg/mL in PBS (pH 7.4) were injected weekly for six weeks. Three 
control mice were treated with PBS only. Tail-bleed (TB) samples were collected three days 
after injection. After the six weeks, the mice were kept untreated for seventeen weeks and re-
immunized with two boost shots of native VHH-7D12 or VHH-9G8. The mice were then 
sacrificed, the heart bleed was collected, and the spleen was gathered for flowcytometric 
analysis. Before each round of injection, we monitored the aggregate's sizes by taking an 
aliquot of the injected sample and measuring the Rh using DLS. All experiments were 
performed in compliance with the Tokyo University of Agriculture and Technology (TUAT) 
and Japanese governmental regulations on animal experimentation. 
3.2.6 Enzyme-linked immunosorbent assay (ELISA) 
ELISA was performed as previously reported [121]. In short, 96-well microtiter plates (TPP 




protein in PBS (pH 7.4) and incubated at 25 °C overnight. After washing the unbound VHH 
with PBS, the plates were blocked with 1% BSA at 37 °C for 45 min. Afterward, 150 µL of 
50 times diluted serum samples were added onto the 1st well followed by 3-fold serial dilution 
in subsequent 0.1% BSA-PBS containing wells and incubated at 37 °C for 2 hours. After 
washing the unbound serum antibodies, 1:3000 diluted anti-mouse IgG-HRP conjugate in 
0.1% BSA-PBS-0.05% Tween-20 were added. After washing the plates with PBS-0.05% 
Tween-20, 100 µL OPD (o-phenylenediamine dihydrochloride) solution was added, and the 
plates were incubated for 20 min for coloring. The coloring reaction was stopped by adding 1 
N sulfuric acid, and the color intensity was measured at 492 nm using a microplate reader 
(SH-9000 Lab, Hitachi High-Tech Science, Japan). Data were analyzed by a power fitting of 
OD 492 nm versus the reciprocal dilution of the anti-sera and a cutoff OD value of 0.1, which 
is above the background value. A previously developed DEN3 ED3 (dengue 3 envelop protein 
3) anti-sera was used as a positive control in all ELISA experiments.  
3.2.7 Cell surface CD marker analysis by flow cytometry 
Experimental samples were prepared according to our previously reported protocol [121]. In 
short, single-cell suspension of mice splenocyte was prepared in FACS buffer (PBS 
supplemented with 2% FBS, 1 mM EDTA, and 0.1% sodium azide). Afterward, 1X red blood 
cell (RBC) lysis buffer (0.15 M ammonium chloride, 10 mM potassium bicarbonate, 0.1 mM 
EDTA) was used to lysis the RBCs. Further, 1 million splenocyte cells in 100 µL of pre-
cooled FACS buffer were surface stained with fluorescence level antibodies according to the 
manufacture guidelines. To study the CD4 T-lymphocytes, cells were stained with anti-CD3-
Pcy5, CD4-Pcy7, CD44-FITC, and CD62LPE-conjugated antibodies in one tube, and CD8 T- 
lymphocytes cells were stained with anti-CD3-Pcy5, CD8-Pcy7, CD44-FITC, and CD62L-
PE-conjugated antibodies in another tube (0.2 μg of antibodies/100 μL) for 30 min in the dark. 
Unbound conjugated antibodies were removed by centrifugation. Finally, cells were 
resuspended in a 500 μL of FACS buffer, and the data were collected using CytoFlex 






3.3.1 Structural and biophysical assessment 
The secondary structure content of VHH-7D12 and VHH-9G8 at pH 7.4 in PBS was assessed 
by circular dichroism (far UV-cd, 200-260 nm). Both VHHs showed a spectrum typical of a β-
sheeted protein (Figure 3.3A). The misfolded VHH-7D12 (VHH-Mis) precipitated in PBS, and 
no spectroscopic measurement was possible in this buffer, but in Na-acetate buffer (pH 4.7), 
where it was soluble and showed CD spectra distinct from the native one (chapter 2, Figure 
2.3A). VHH-7D12 and VHH-9G8 appeared to be monomeric as suggested by a hydrodynamic 
radius (Rh) of around 2 nm as measured by DLS, whereas VHH-Mis exhibited a larger Rh value, 
indicating its aggregated state (Figure 3.4A and Table 3.1). These results were corroborated 
by static light scattering (SLS) (Figure 3.4B and Table 3.1). 
3.3.2 A strong immune response generated by the aggregated VHH-Mis 
The mice were immunized weekly once for six times with the misfolded VHH-7D12 (VHH-
Mis). The serum IgG response against the native VHH-7D12 and VHH-9G8 was monitored for 
26 weeks by measuring the IgG titer using ELISA with plates coated with native VHH-7D12 
or VHH-9G8. As a control, we immunized two groups of mice with the native monomeric VHH-
7D12 and VHH-9G8. First, we examined the anti-sera just after completing the primary 
immunization (TB-6, Scheme: 1). Both native VHHs were barely immunogenic (Figure 3.5A), 
as expected for small proteins, and in line with our previous report [142]. In contrast, mice 
immunized with aggregated VHH-Mis, which had altered secondary and tertiary structures 
(Figure 3.3A and B), showed a strong IgG titer against the native VHH-7D12. The results are 
in line with our previous report, where we showed that amorphous aggregates of misfolded 
VHH-7D12 increased the immune response against the native VHH-7D12 in mice; but 
denatured aggregates induced by heat stress did not, even though the aggregates’ sizes were 
almost identical. We thus concluded that the biophysical and biochemical nature of the 
misfolded aggregates are critical in generating ADAs against the native VHH-7D12 [140]. 
Indeed, the IgG titers against the native VHH-7D12 were stronger in twelve mice out of the 





Furthermore, the anti-sera raised against VHH-Mis, during the primary round of immunization, 
were analyzed by ELISA by using both the native VHH-7D12 and VHH-9G8 as coating 
antigens. This is because we anticipated seeing cross-reaction because of their nearly identical 
frameworks (Figure 3.2A). 60% of mice (8 out of 13)  immunized with VHH-Mis exhibited a 
serum IgG response against native VHH-7D12 that was much stronger than against native VHH-
9G8 (Figure 3.6 and Table 3.2). The remaining mice (5 out of 13 or 40%) exhibited a nearly 
identical IgG response against the native VHH-7D12 and VHH-9G8. According to IgG 
specificity, we divided the VHH-Mis immunized mice (n=13) into two groups: Group-1, 
which included the mice showing a strong IgG titer against the native VHH-7D12 but a weak 
one if any against the native VHH-9G8 (n=8); Group-2, which included the mice showing very 
similar IgG titer against native VHH-7D12 and VHH-9G8 (n=5) (Table 3.2). In the next section, 
we analyze the extent of the breakage of the immune tolerance generated by the misfolded 
VHH-7D12 (VHH-Mis).  
3.3.3 Nature of the long term immune response against the native VHHs 
We thus asked whether VHH-Mis would generate a long-lasting immune memory against the 
native VHH-9G8, whose framework region is very similar to that of VHH-7D12 but has distinct 
CDRs (Figure 3.2A). After 17 weeks of without injection, the mice were re-immunized (boost 
injection) using either native VHH-7D12 or native VHH-9G8. Three mice of Group-1 (M1, M3, 
and M9) were re-immunized with native VHH-9G8 (Figure 3.7), and two mice (M10 and M11) 
were re-immunized with native VHH-7D12 (Figure 3.8). By re-immunizing with native VHH-
7D12, the serum IgG titer substantially increased after two injections, suggesting the presence 
of immunological memory against native VHH-7D12 (Figure 3.8). Oppositely, re-
immunization with VHH-9G8 did not increase the titer against VHH-7D12 or even against VHH-
9G8 (Figure 3.7). This suggested that the immune memory in Group-1 mice was generated 
against regions of VHH that are specific to VHH-7D12, i.e., the CDRs. Next, Group-2 mice 
(M12 and M13) re-immunized with native VHH-7D12 increased their anti-VHH-7D12 IgG titer 
sharply, even much higher than primary immunization with VHH-Mis (except M13), but not 
against VHH-9G8 (Figure 3.10). The remaining Group-2 mice (M2, M4, and M7) were re-




as the increase needed one more week to appear (TB-26) than when the mice were re-
immunized with native VHH-7D12 (Figure 3.9). 
3.3.4 Immunization with VHH-Mis established T-cell effector and central memory 
The generation of immunological memory was further analyzed by cell surface CD markers 
in mice that responded strongly to re-immunization with native VHH-7D12. The mice were 
sacrificed 26 weeks after the first immunization and their spleen collected for CD analysis. 
The mice primarily immunized with native VHH-7D12 (as a control) had a low number of 
CD44+ and high CD62L+ CD4 (T-helper) (Figure 3.11) and CD8 (T-cytolytic) cells (Figure 
3.12). Moreover, a higher number of CD44-CD62L+ co-expressing T-helper (77%) and T-
cytolytic (74%) cells was observed, indicating their naïve immunological status (Figure 3.13).  
On the other hand, the VHH-Mis immunized mice showed a high number of CD44+ and low 
CD62L+ (both CD4 and CD8 cells) population (Figure 3.11 and 3.12). Additionally, a lower 
percentage of CD44-CD62L+ cells, and a higher percentage of CD44+CD62L+ and 
CD44+CD62L- co-expressing T-helper and T-cytolytic cells were observed (Figure 3.13), 







Therapeutic proteins, the largest and fastest-growing class of biopharmaceutical product, can 
provoke ADAs [143-145]. Aggregation is a critical factor causing the undesired immune 
response affecting the protein's therapeutic properties [57, 129], and clinical observations 
relating ADAs with aggregates have been reported for human growth hormone (hGH) [21, 
22]. However, amorphous aggregates of different sizes [35, 37, 40, 146] and distinct 
biophysical and biochemical attributes are formed depending on how they are generated [147-
150], which may result in ADAs having distinct properties [33, 39, 132]. For instance, ADAs 
may bind near the active site or apart from the active site (so-called neutralizing or non-
neutralizing, respectively) [7, 151], however, in any case, ADAs can alter a protein’s 
therapeutic efficiency by accelerating its clearance from the organs and the body, as clinically 
shown for adalimumab [152]. Alternatively, ADAs may recognize a host endogenous protein, 
which could induce serious side effects, as seen with recombinant erythropoietin [5]. 
The misfolded VHH-7D12 (VHH-Mis), which were functionally inactive (Figure 3.15), 
induced an IgG response in 60% mice (Group-1), hypothesized as being directed against VHH-
7D12's CDRs, because the anti-VHH-7D12 IgG titer was much stronger than the anti-VHH-9G8 
titer. The rationale for the CDRs specificity is unclear from a protein structural viewpoint 
since the CDR’s conformation in the misfolded VHH-7D12 is expected to be different from 
that in the native VHH-7D12. Re-immunizing these mice with native VHH-7D12 sharply 
increased the immune response against the native VHH-7D12 (Figure 3.8), however, no mice 
showed such a response by re-immunizing with native VHH-9G8 (Figure 3.7), suggesting an 
immunological memory against the CDRs of native VHH-7D12 was established. We thus 
speculate that the CDRs of misfolded VHH-7D12 have a structure similar to that in the native 
VHH-7D12, which are constrained but flexible loops (Figure 3.2A). Our observation is 
essentially in line with a previous report showing that rhIFNβ-1a aggregates generate 
neutralizing ADAs targeting the native rhIFNβ-1a [128]. Noteworthy, a similar phenomenon 
was also observed by re-immunizing the Group-1 mice with the misfolded VHH-7D12 (VHH-
Mis). 
Cross-reactive and pre-existing antibodies create much concern as they may reduce the related 




biosimilar to infliximab, recognize both CT-P13 and infliximab and neutralize their function 
[153]. In our experiment, cross-reaction was observed in group-2 mice (40%), where the 
immune response against VHH-7D12 and VHH-9G8 were of similar strength. Furthermore, 
Group-2 mice re-immunized with the native VHH-7D12 produced anti-sera recognizing the 
native VHH-7D12 more strongly than the native VHH-9G8, suggesting the presence of IgG 
antibodies targeting the VHH-7D12’s CDRs (Figure 3.10). We initially expected Group-2 
mice would respond upon re-immunization with native VHH-9G8 as strongly as observed with 
VHH-7D12, but we observed a relatively slower and moderate immune response (Figure 3.9). 
Moreover, their specificity was essentially unchanged (Figure 3.9), unlike the immune 
response that we observed by re-immunizing the mice with native VHH-7D12. These results 
suggest that the risks of ADAs generation by subsequent injections are high when the same 
protein, even natively folded, is used, but they remain low-to-moderate when a biosimilar 
analog is used. 
Immune responses against aggregated proteins can occur through a T-cell dependent (TD) 
pathway or a T-cell independent (TI) pathway [24, 154]. In a TD pathway, the recognition of 
antigenic epitopes by B-cell receptors (BCRs) provides the first signal for B-cells activation 
and the second signal comes from the T-cells, which are activated by antigen-presenting cells 
(APCs), primed with the same antigen [24]. B-cell Ig isotype switching and immunological 
memory are generated by the TD pathway, resulting in a long-lasting immunogenic response. 
Here, we found that VHH-Mis immunized mice had a higher CD44+ cell population. 
Furthermore, both CD4+ (T-helper cell) and CD8+ (T-cytolytic) showed an increased number 
of  CD44+CD62L+ and CD44+CD62L- co-expressed cell population, which strongly 
indicates the generation of central and effector memory T-cells [155]. Moreover, VHH-Mis 
induced a long-lasting anti-VHH serum IgG response, particularly the IgG1 response (Figure 
3.14), which are indicative of Th2 skewed immune response [38]. Such long-lasting ADAs 
response was observed in a clinical study with INF-β [156] and other therapeutic mAbs [157].  
According to the ADAs model, the persistent generation of serum IgG will affect the drug's 







Amorphous aggregation of therapeutic antibodies and antibody fragments is the focus of much 
attention as it may decline drug safety and cause severe side effects in the form of ADAs. 
Previously, we showed how aggregate's biophysical and biochemical properties of VHH 
antibody influenced the immunogenic response [140]. Our current observations indicate that 
the immunological memory developed by amorphous aggregates made of misfolded VHH can 
induce substantial and long-lasting ADAs against its native self. However, the response 
against an analogous VHH having an almost identical framework region but different CDRs 
was less severe (60% in our experimental setting). This observation indeed suggests that by 
determining the ADAs specificity one might avoid ADAs' appearance by switching the 
therapeutic antibody to an analogous one that targets the same EGFR and would thus allow 
keeping the same therapeutic strategy. We hope that such a conclusion will remain valid for 
therapeutic VHHs and other antibody drugs since they hold similar structural properties with 








Figure 3.1. Determination of molecular weight of purified VHHs. Purified VHH protein 
identities were analyzed by MALDI-TOF mass spectroscopy (autoflex speed TOF/TOF, US) 
(A) Native VHH-7D12 (Mw: 14560.21 Da) and (B) Native VHH-9G8 (Mw: 15164.92 Da). The 
theoretical molecular weight of VHH-7D12 and VHH-9G8 calculated from ExPASy ProtParam 
was 14559.95 Da and 15169.69, respectively, which is almost identical to our measured 





Figure 3.2. Structure of anti-EGFR VHH-7D12 and VHH-9G8 antibodies and schematic 
representation of immunization. (A) Surface model representation of the VHH-7D12, VHH-
9G8, and their superimpose image generated using Pymol (PDB ID 4KRL and 4KRP, 
respectively); and their sequence alignment. They have 89% framework and 77% overall 
sequence similarities. Gray, deep gray and black indicate the complementarity determining 
region 1 (CDR1), CDR2, and CDR3, respectively. (B) The schematic of immunization. In 
Scheme 1, each group of mice was immunized (IM) with individual VHH formulation once a 
week (up to six weeks), and tail bleed (TB) samples were collected three days after each round 
of immunization and performed ELISA. In Scheme 2, VHH-Mis immunized mice were kept 
untreated for 17 weeks. Only the serum IgG level was monitored by ELISA using tail bleed 
samples from TB-7 to TB-23 (white box). Afterward, mice were re-immunized with native 
VHH-7D12, native VHH-9G8, or VHH-Mis and performed TB-24 and TB-25 (deep gray box). 


























Figure 3.3. Secondary and tertiary structural properties of anti-EGFR VHH: (A) Circular 
dichroism (cd) spectra at 37 °C and (B) Tryptophan fluorescence spectra at 37 °C. All protein 
samples were formulated in PBS, pH 7.4, at a concentration of 0.3 mg/mL. Three 

























































































Figure 3.4. Aggregates size measurement by DLS and SLS: All protein samples were 
formulated in PBS, pH 7.4, at a concentration of 0.3 mg/mL (A) Aggregate’s size of VHHs 
measured by dynamic light scattering (DLS): spectra of size distribution in number (%) at 37 
°C. (B) Aggregation intensities of VHHs at 37 °C measured by SLS at a wavelength of 600 
nm. The misfolded VHH-7D12 (VHH-Mis) showed higher scattering intensity, indicating its 
aggregated state, whereas native VHH-7D12 and VHH-9G8 showed a minimum scattering 










































































Figure 3.5: Anti-VHH IgG titer by ELISA. ELISA was performed using tail bleed serum 
samples after six doses of subcutaneous immunization (TB-6). (A) anti-VHH IgG titer of 
different VHHs formulations. ELISA plates were coated with native VHH-7D12 or native VHH-
9G8 to measure the serum IgG titer of their respective formulations. Each circle indicates the 
individual's mice titer, and bars show the average titer. The total number of mice in each group 
and the number of mice accounting for average titer calculation are shown in parentheses. (B) 
























































Figure 3.6: Specificity of VHH-Mis anti-sera against native VHH-7D12 and VHH-9G8 
assayed by ELISA: ELISA plate were coated with native VHH-7D12 and native VHH-9G8. 














































Figure 3.7: Re-immunization of Group-1 mice with native VHH-9G8 (Scheme-2). (A) 
Long-term anti-VHH-7D12 IgG titers of mice M1, M3 and M9, and the IgG titers after re-
immunization with two boost shots of native VHH-9G8 (TB-24 and TB-25). TB-26 was 
performed without immunization. (B) Specificity against native VHH-7D12 and native VHH-




















































































Figure 3.8: Re-immunization of Group-1 mice with native VHH-7D12 (Scheme-2). (A) 
Long-term anti-VHH-7D12 IgG titers of mice M10 and M11, and the IgG titers after re-
immunization with two boost shots of native VHH-9G8 (TB-24 and TB-25). (B) Specificity 
against native VHH-7D12 and native VHH-9G8 just before (TB-23) and after re-immunization 




































































Figure 3.9: Re-immunization of Group-2 mice with native VHH-9G8 (Scheme-2). (A) 
Long-term anti-VHH-7D12 IgG titers of mice M2, M4 and M7, and the IgG titers after re-
immunization with two boost shots of native VHH-9G8 (TB-24 and TB-25). TB-26 was 
performed without immunization. (B) Specificity against native VHH-7D12 and native VHH-
















































































Figure 3.10: Re-immunization of Group-2 mice with native VHH-7D12 (Scheme-2). (A) 
Long-term anti-VHH-7D12 IgG titers of mice M12 and M13, and the IgG titers after re-
immunization with two boost shots of native VHH-9G8 (TB-24 and TB-25). (B) Specificity 
against native VHH-7D12 and native VHH-9G8 just before (TB-23) and after re-immunization 


















































Figure 3.11. Flow-cytometry analysis of cell surface CD (cluster of differentiation) 
markers (T-helper cells). A single-cell suspension of mice splenocytes in FACS buffer was 
used for flow-cytometry analysis. Differential expressions of cell surface (A) CD44 and (B) 
CD 62Lmarkers induced by native and aggregated misfolded VHH-7D12 (VHH-Mis) on T-
helper cell (CD4+). VHH-Mis immunized mice had a very high population of CD44+ Th-cell 









Figure 3.12. Flow-cytometry analysis of cell surface CD (cluster of differentiation) 
markers (T-cytolytic cells). A single-cell suspension of mice splenocytes in FACS buffer 
was used for flow-cytometry analysis. Differential expressions of cell surface (A) CD44 and 
(B) CD62L markers induced by native and aggregated misfolded VHH-7D12 (VHH-Mis) on T-
cytolytic cell (CD8+). VHH-Mis immunized mice had a very high population of CD44+ Tc-








Figure 3.13. Characterization of effector and central T-cell memory by flow cytometry. 
A single-cell suspension of mice splenocytes in FACS buffer was used for flow-cytometry 
analysis. Co-expression patterns of CD44 and CD62L on Th-cell (CD4 positive cell) and Tc-
cell (CD8 positive cell) are shown in panels (A) and (B), respectively. VHH-Mis induced a 
higher proportion of CD44+CD62L+ and CD44+CD62L- expressed Th and Tc cell than that 















Figure 3.14. Determination of IgG sub-class by ELISA. ELISA experiment was performed 
following the method explained in the main text. Tail bleed 6 (TB-6) serum sample was used 


































Figure 3.15. Binding activity measurement by surface plasmon resonance (SPR): 
The binding affinity of the anti-EGFR VHHs to the extracellular domain of human EGFR 
(Abcam, UK) was carried out by SPR. In short, the EGFR extracellular domain was first 
immobilized onto the CM5 sensor chip (Biacore 2000, GE Healthcare, USA) according to the 
manufacturer's guidance. SPR was measured at concentrations between 6.0 and 0.046 μg/mL 
at 20 °C and at a flow rate of 30 µL/min in 10 mM HBS-EP buffer, pH 7.4, (10 mM HEPES, 
150 mM NaCl, 3 mM EDTA, and 0.005% surfactant P20). SPR sonogram of (A) VHH-7D12 


















Table 3.1. Aggregate's size by DLS and SLS 
VHHs formulation Hydrodynamic radius (Rh) by 
DLS 
Light scattering intensity by 
SLS 
VHH-7D12 1.9 ± 0.10 18.70±1.29 
VHH-9G8 1.98 ± 0.11 23.01±0.50 
VHH-Mis 1115.81 ± 312.50 6194.57±84.64 
All proteins were formulated at a final concentration of 0.3 mg/mL in PBS. The values are the average 






Table 3.2. Serum IgG titer of VHH-Mis immunized mice against native VHH-7D12 and VHH-
9G8 
Group-1  
Mice ID TB-6 
VHH-7D12 VHH-9G8 
M1 13565±605 513±21 
M3 6099±170 889±60 
M5 6873±21 2331±127 
M6 9056±1045 2515±287 
M8 6814±575 788±11 
M9 2433±50 388±56 
M10 9525±1299 5022±162 
M11 16595±83 1367±151 
Group-2  
M2 6318±109 6024±350 
M4 11455±762 10109±1262 
M7 15669±625 13537±605 
M12 9344±116 8253±280 
M13 11540±466 12154±121 
TB: Tail bleed; M: Mouse identities 
ELISA plates were coated with native VHH-7D12 and native VHH-9G8. The titer values are the 























Engineered antibody and antibody fragments are a fast-growing class of biotherapeutic 
protein. The generation of anti-drug antibodies (ADAs) is one of the major concerns in 
biotherapeutic drug development. Even though many of the intrinsic and extrinsic factors 
influence the anti-drug antibodies generation, protein amorphous aggregation identifies as a 
critical one. So far, many of the experimental studies have focused on examining the sizes of 
amorphous aggregates that generate ADAs, but counter-examples have led to some 
controversy, and it now appears that amorphous aggregates can possess unique biophysical 
attributes other than their sizes. In this dissertation, I systematically showed that amorphous 
aggregates with very similar size but distinct biochemical and biophysical nature can generate 
different immunogenicity. Two misfolded (VHH-Ins and VHH-Mis) and two heat-induced 
aggregates (VHH-95 and VHH-65) were generated from an anti-EGFR VHH antibody (VHH-
7D12), a potential anti-cancer drug. Both of the misfolded VHHs and VHH-95 (complete 
denatured) formed aggregates with hydrodynamic radii of ~2 µm according to DLS 
measurements, but distinct with their biochemical (intermolecular SS bonds) and biophysical 
properties (folded/unfolded). As such, the misfolded VHHs (VHH-Mis and VHH-Ins) showed 
higher immunogenicity in mice model than heat-induced VHH-95 aggregates, which formed 
through complete denaturation. This study shows that the biophysical and biochemical nature 
of aggregates play a vital role in generating ADAs, rather than the size of the aggregates, as 
we imagined so far, and expected to pave the way toward a deeper understanding of the 
immunogenic mechanism associated with aggregated therapeutic protein. Moreover, in a 
follow-up study with misfolded VHH-7D12 (VHH-Mis) aggregates we investigated the 
immunological memory and long-term ADAs generation risk, which rarely monitored any of 




immunological memory recognizing the natively folded VHH-7D12’s CDRs (60% mice). Such 
IgG and immunological memory can not recognize the analogous VHH antibody-drug (VHH-
9G8 in our study), having similar antibody frameworks but distinct CDRs and thus safer for 
replacing the analogous VHH antibody drugs for treatment. This observation indeed suggests 
that by determining the ADAs specificity one might avoid ADAs' appearance by switching 
the therapeutic antibody to an analogous one that targets the same EGFR and would thus allow 
keeping the same therapeutic strategy. The remaining 40% of the mice generated IgG and 
long-term immunological memory that recognizing both of the VHHs (VHH-7D12 and VHH-
9G8), indicating that the immunological response is generated against the framework regions 
that are common for both VHHs. Such immune responses carry the long-term ADAs generation 
risk not only for the self VHH (against immune response are generated, in this study VHH-
7D12) but also for analogous VHH antibody (hold similar framework but different CRDs, thus 
functioning differently, in this study VHH-9G8).  As such, this study is expected to pave the 
way toward a deeper understanding of the long-term and cross responsive immune response 
against related drug molecules, particularly for the therapeutic monoclonal antibodies (mAbs) 
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